HRP20050248A2 - Heterocyclic substituted piperazines for the treatment of schizophrenia - Google Patents
Heterocyclic substituted piperazines for the treatment of schizophreniaInfo
- Publication number
- HRP20050248A2 HRP20050248A2 HR20050248A HRP20050248A HRP20050248A2 HR P20050248 A2 HRP20050248 A2 HR P20050248A2 HR 20050248 A HR20050248 A HR 20050248A HR P20050248 A HRP20050248 A HR P20050248A HR P20050248 A2 HRP20050248 A2 HR P20050248A2
- Authority
- HR
- Croatia
- Prior art keywords
- quinolin
- disorders
- dihydro
- disorder
- ethyl
- Prior art date
Links
- 201000000980 schizophrenia Diseases 0.000 title claims description 19
- 125000000623 heterocyclic group Chemical group 0.000 title claims description 9
- 150000004885 piperazines Chemical class 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 269
- 238000000034 method Methods 0.000 claims description 157
- 208000028017 Psychotic disease Diseases 0.000 claims description 79
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 61
- 208000035475 disorder Diseases 0.000 claims description 61
- 208000019901 Anxiety disease Diseases 0.000 claims description 53
- 150000003839 salts Chemical class 0.000 claims description 45
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 39
- -1 nitro, cyano, amino Chemical group 0.000 claims description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 35
- 230000036506 anxiety Effects 0.000 claims description 35
- 208000020401 Depressive disease Diseases 0.000 claims description 33
- 125000001153 fluoro group Chemical group F* 0.000 claims description 31
- 206010012289 Dementia Diseases 0.000 claims description 30
- 208000023105 Huntington disease Diseases 0.000 claims description 30
- 208000016285 Movement disease Diseases 0.000 claims description 30
- 208000018737 Parkinson disease Diseases 0.000 claims description 30
- 239000003176 neuroleptic agent Substances 0.000 claims description 30
- 230000000701 neuroleptic effect Effects 0.000 claims description 30
- 208000020925 Bipolar disease Diseases 0.000 claims description 26
- 208000024732 dysthymic disease Diseases 0.000 claims description 26
- 208000024714 major depressive disease Diseases 0.000 claims description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 26
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 24
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 23
- 208000015238 neurotic disease Diseases 0.000 claims description 23
- 229940079593 drug Drugs 0.000 claims description 22
- 208000024827 Alzheimer disease Diseases 0.000 claims description 20
- 208000008811 Agoraphobia Diseases 0.000 claims description 18
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 18
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 18
- 230000003542 behavioural effect Effects 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 208000019022 Mood disease Diseases 0.000 claims description 16
- 208000028683 bipolar I disease Diseases 0.000 claims description 16
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 15
- 229910052799 carbon Inorganic materials 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 241000124008 Mammalia Species 0.000 claims description 13
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 208000024254 Delusional disease Diseases 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 208000002851 paranoid schizophrenia Diseases 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 206010001541 Akinesia Diseases 0.000 claims description 10
- 208000020706 Autistic disease Diseases 0.000 claims description 10
- 206010008748 Chorea Diseases 0.000 claims description 10
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 10
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 10
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 10
- 206010012218 Delirium Diseases 0.000 claims description 10
- 208000012661 Dyskinesia Diseases 0.000 claims description 10
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 10
- 208000031886 HIV Infections Diseases 0.000 claims description 10
- 206010019196 Head injury Diseases 0.000 claims description 10
- 208000026139 Memory disease Diseases 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 10
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 10
- 201000005625 Neuroleptic malignant syndrome Diseases 0.000 claims description 10
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 10
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 10
- 206010034010 Parkinsonism Diseases 0.000 claims description 10
- 206010034912 Phobia Diseases 0.000 claims description 10
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 10
- 201000000552 Scott syndrome Diseases 0.000 claims description 10
- 206010039966 Senile dementia Diseases 0.000 claims description 10
- 206010041250 Social phobia Diseases 0.000 claims description 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 10
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 10
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 10
- 208000016620 Tourette disease Diseases 0.000 claims description 10
- 206010044565 Tremor Diseases 0.000 claims description 10
- 201000004810 Vascular dementia Diseases 0.000 claims description 10
- 230000001154 acute effect Effects 0.000 claims description 10
- 229940049706 benzodiazepine Drugs 0.000 claims description 10
- 208000010877 cognitive disease Diseases 0.000 claims description 10
- 230000001149 cognitive effect Effects 0.000 claims description 10
- 208000026725 cyclothymic disease Diseases 0.000 claims description 10
- 208000010118 dystonia Diseases 0.000 claims description 10
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 10
- 208000037860 neuroleptic-induced Akathisia Diseases 0.000 claims description 10
- 208000019906 panic disease Diseases 0.000 claims description 10
- 208000013667 paroxysmal dyskinesia Diseases 0.000 claims description 10
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 10
- 230000000306 recurrent effect Effects 0.000 claims description 10
- 208000018198 spasticity Diseases 0.000 claims description 10
- 201000001716 specific phobia Diseases 0.000 claims description 10
- 239000011593 sulfur Substances 0.000 claims description 10
- 208000011580 syndromic disease Diseases 0.000 claims description 10
- 239000013543 active substance Substances 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
- 239000001301 oxygen Chemical group 0.000 claims description 9
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 8
- SRAQFALNAGNAQE-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-1,3-dihydroquinolin-2-one Chemical compound N1C(=O)CC(C)(C)C2=C1C(C)=CC(CCN1CCN(CC1)C=1C3=CC=CC=C3SN=1)=C2 SRAQFALNAGNAQE-UHFFFAOYSA-N 0.000 claims description 8
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 claims description 8
- 206010012239 Delusion Diseases 0.000 claims description 8
- 206010012335 Dependence Diseases 0.000 claims description 8
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims description 8
- 206010016275 Fear Diseases 0.000 claims description 8
- 208000010412 Glaucoma Diseases 0.000 claims description 8
- 208000004547 Hallucinations Diseases 0.000 claims description 8
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 8
- 206010022998 Irritability Diseases 0.000 claims description 8
- 206010026749 Mania Diseases 0.000 claims description 8
- 208000036626 Mental retardation Diseases 0.000 claims description 8
- 208000022873 Ocular disease Diseases 0.000 claims description 8
- 206010034158 Pathological gambling Diseases 0.000 claims description 8
- 208000001431 Psychomotor Agitation Diseases 0.000 claims description 8
- 206010037213 Psychomotor retardation Diseases 0.000 claims description 8
- 208000027465 Psychotic Affective disease Diseases 0.000 claims description 8
- 206010038743 Restlessness Diseases 0.000 claims description 8
- 208000017442 Retinal disease Diseases 0.000 claims description 8
- 206010038923 Retinopathy Diseases 0.000 claims description 8
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 claims description 8
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 8
- 208000013200 Stress disease Diseases 0.000 claims description 8
- 206010068932 Terminal insomnia Diseases 0.000 claims description 8
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims description 8
- 208000012826 adjustment disease Diseases 0.000 claims description 8
- 125000003282 alkyl amino group Chemical group 0.000 claims description 8
- 208000022531 anorexia Diseases 0.000 claims description 8
- 239000000935 antidepressant agent Substances 0.000 claims description 8
- 229940005513 antidepressants Drugs 0.000 claims description 8
- 208000025748 atypical depressive disease Diseases 0.000 claims description 8
- 230000006399 behavior Effects 0.000 claims description 8
- 208000022257 bipolar II disease Diseases 0.000 claims description 8
- 208000030963 borderline personality disease Diseases 0.000 claims description 8
- 229960003920 cocaine Drugs 0.000 claims description 8
- 206010061428 decreased appetite Diseases 0.000 claims description 8
- 231100000868 delusion Toxicity 0.000 claims description 8
- 229960002069 diamorphine Drugs 0.000 claims description 8
- 208000035548 disruptive behavior disease Diseases 0.000 claims description 8
- 206010020765 hypersomnia Diseases 0.000 claims description 8
- 206010022437 insomnia Diseases 0.000 claims description 8
- 230000000302 ischemic effect Effects 0.000 claims description 8
- 201000003995 melancholia Diseases 0.000 claims description 8
- 230000007659 motor function Effects 0.000 claims description 8
- 208000025319 neurotic depression Diseases 0.000 claims description 8
- 229960002715 nicotine Drugs 0.000 claims description 8
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 8
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 8
- 208000012672 seasonal affective disease Diseases 0.000 claims description 8
- 208000011117 substance-related disease Diseases 0.000 claims description 8
- 208000016261 weight loss Diseases 0.000 claims description 8
- 230000004580 weight loss Effects 0.000 claims description 8
- 239000002249 anxiolytic agent Substances 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- AKILNVRTEPFPLQ-UHFFFAOYSA-N 6-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-3,3-dimethyl-1,4-dihydroquinolin-2-one Chemical class C1=CC=C2C(N3CCN(CC3)CCCC=3C=C4CC(C(NC4=CC=3)=O)(C)C)=NSC2=C1 AKILNVRTEPFPLQ-UHFFFAOYSA-N 0.000 claims description 6
- BVHBZOKJMIKPOZ-UHFFFAOYSA-N 6-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-3-methyl-3,4-dihydro-1h-quinolin-2-one Chemical class C1=CC=C2C(N3CCN(CC3)CCCC=3C=C4CC(C(NC4=CC=3)=O)C)=NSC2=C1 BVHBZOKJMIKPOZ-UHFFFAOYSA-N 0.000 claims description 6
- WJMJAABZHXLYBK-UHFFFAOYSA-N 6-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-4-methyl-3,4-dihydro-1h-quinolin-2-one Chemical class C1=CC=C2C(N3CCN(CC3)CCCC3=CC=C4NC(=O)CC(C4=C3)C)=NSC2=C1 WJMJAABZHXLYBK-UHFFFAOYSA-N 0.000 claims description 6
- HYBUGTIRHHFEPD-UHFFFAOYSA-N 6-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-7-chloro-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical class C1=CC=C2C(N3CCN(CC3)CCCC3=C(Cl)C=C4NC(=O)CC(C4=C3)(C)C)=NSC2=C1 HYBUGTIRHHFEPD-UHFFFAOYSA-N 0.000 claims description 6
- 230000001430 anti-depressive effect Effects 0.000 claims description 6
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical group C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- UYUFZPABHRNZTC-UHFFFAOYSA-N 6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(=O)CC(C4=C3)C)=NOC2=C1 UYUFZPABHRNZTC-UHFFFAOYSA-N 0.000 claims description 5
- SKNIGTOGXCSMPA-UHFFFAOYSA-N 6-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-3,3-dimethyl-1,4-dihydroquinolin-2-one Chemical class C1=CC=C2C(N3CCN(CC3)CCCC=3C=C4CC(C(NC4=CC=3)=O)(C)C)=NOC2=C1 SKNIGTOGXCSMPA-UHFFFAOYSA-N 0.000 claims description 5
- FWIJCAZWYWIOGO-UHFFFAOYSA-N 6-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-3-methyl-3,4-dihydro-1h-quinolin-2-one Chemical class C1=CC=C2C(N3CCN(CC3)CCCC=3C=C4CC(C(NC4=CC=3)=O)C)=NOC2=C1 FWIJCAZWYWIOGO-UHFFFAOYSA-N 0.000 claims description 5
- PSKPYRZXGUASSX-UHFFFAOYSA-N 6-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-4-methyl-3,4-dihydro-1h-quinolin-2-one Chemical class C1=CC=C2C(N3CCN(CC3)CCCC3=CC=C4NC(=O)CC(C4=C3)C)=NOC2=C1 PSKPYRZXGUASSX-UHFFFAOYSA-N 0.000 claims description 5
- JRIIIUATLVQNQZ-UHFFFAOYSA-N 6-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-7-chloro-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical class C1=CC=C2C(N3CCN(CC3)CCCC3=C(Cl)C=C4NC(=O)CC(C4=C3)(C)C)=NOC2=C1 JRIIIUATLVQNQZ-UHFFFAOYSA-N 0.000 claims description 5
- WVANIHWRGJZWQE-UHFFFAOYSA-N 6-[3-[4-(1h-indazol-3-yl)piperazin-1-yl]propyl]-3,3-dimethyl-1,4-dihydroquinolin-2-one Chemical class C1=CC=C2C(N3CCN(CC3)CCCC=3C=C4CC(C(NC4=CC=3)=O)(C)C)=NNC2=C1 WVANIHWRGJZWQE-UHFFFAOYSA-N 0.000 claims description 5
- XLXQCJTZPKZZHA-UHFFFAOYSA-N 6-[3-[4-(1h-indazol-3-yl)piperazin-1-yl]propyl]-3-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCCC=3C=C4CC(C(NC4=CC=3)=O)C)=NNC2=C1 XLXQCJTZPKZZHA-UHFFFAOYSA-N 0.000 claims description 5
- DSXFKXJQTXWPRC-UHFFFAOYSA-N 6-[3-[4-(1h-indazol-3-yl)piperazin-1-yl]propyl]-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical class C1=CC=C2C(N3CCN(CC3)CCCC3=CC=C4NC(=O)CC(C4=C3)(C)C)=NNC2=C1 DSXFKXJQTXWPRC-UHFFFAOYSA-N 0.000 claims description 5
- DYETXXQBGKPREH-UHFFFAOYSA-N 6-[3-[4-(1h-indazol-3-yl)piperazin-1-yl]propyl]-4-methyl-3,4-dihydro-1h-quinolin-2-one Chemical class C1=CC=C2C(N3CCN(CC3)CCCC3=CC=C4NC(=O)CC(C4=C3)C)=NNC2=C1 DYETXXQBGKPREH-UHFFFAOYSA-N 0.000 claims description 5
- 208000020016 psychiatric disease Diseases 0.000 claims description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- KWWOAPIFJXWASC-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-7-chloro-4,4,8-trimethyl-1,3-dihydroquinolin-2-one;methanesulfonic acid Chemical class CS(O)(=O)=O.N1C(=O)CC(C)(C)C2=C1C(C)=C(Cl)C(CCN1CCN(CC1)C=1C3=CC=CC=C3SN=1)=C2 KWWOAPIFJXWASC-UHFFFAOYSA-N 0.000 claims description 4
- BIJZPRUJELIQNV-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-7-fluoro-4,4,8-trimethyl-1,3-dihydroquinolin-2-one;hydrochloride Chemical class Cl.N1C(=O)CC(C)(C)C2=C1C(C)=C(F)C(CCN1CCN(CC1)C=1C3=CC=CC=C3SN=1)=C2 BIJZPRUJELIQNV-UHFFFAOYSA-N 0.000 claims description 4
- PYLOOAAZCQAYIV-UHFFFAOYSA-N 6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-3,3,4-trimethyl-1,4-dihydroquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C(C(=O)NC4=CC=3)(C)C)C)=NOC2=C1 PYLOOAAZCQAYIV-UHFFFAOYSA-N 0.000 claims description 4
- HMMNBVXJFGFCOH-UHFFFAOYSA-N 6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-1,4-dihydroquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(C(NC4=CC=3)=O)(C)C)=NOC2=C1 HMMNBVXJFGFCOH-UHFFFAOYSA-N 0.000 claims description 4
- XAEHXWOCDYSLNZ-UHFFFAOYSA-N 6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C)C(C(NC4=CC=3)=O)C)=NOC2=C1 XAEHXWOCDYSLNZ-UHFFFAOYSA-N 0.000 claims description 4
- ICYAYJZMSZYRTH-UHFFFAOYSA-N 6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(=O)CC(C4=C3)(C)C)=NOC2=C1 ICYAYJZMSZYRTH-UHFFFAOYSA-N 0.000 claims description 4
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- UYUFZPABHRNZTC-MRXNPFEDSA-N (4r)-6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(=O)C[C@H](C4=C3)C)=NOC2=C1 UYUFZPABHRNZTC-MRXNPFEDSA-N 0.000 claims description 3
- FVKASEBIOGTGPW-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-3,3,4-trimethyl-1,4-dihydroquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C(C(=O)NC4=CC=3)(C)C)C)=NSC2=C1 FVKASEBIOGTGPW-UHFFFAOYSA-N 0.000 claims description 3
- QAHPXFKRKNPFBI-UHFFFAOYSA-N 6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-1,4,4-trimethyl-3h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)CC(=O)N(C4=CC=3)C)=NOC2=C1 QAHPXFKRKNPFBI-UHFFFAOYSA-N 0.000 claims description 3
- SFQXSVYGMCMNIR-UHFFFAOYSA-N 6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-1,4-dimethyl-3,4-dihydroquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4N(C)C(=O)CC(C4=C3)C)=NOC2=C1 SFQXSVYGMCMNIR-UHFFFAOYSA-N 0.000 claims description 3
- VUUTVDVGKRASMV-UHFFFAOYSA-N 6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(C(NC4=CC=3)=O)C)=NOC2=C1 VUUTVDVGKRASMV-UHFFFAOYSA-N 0.000 claims description 3
- LPQGFAHTFZZRMH-UHFFFAOYSA-N 6-[2-[4-(1h-indazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-1,4-dihydroquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(C(NC4=CC=3)=O)(C)C)=NNC2=C1 LPQGFAHTFZZRMH-UHFFFAOYSA-N 0.000 claims description 3
- ZGXRKIVHNAJFGW-UHFFFAOYSA-N 6-[2-[4-(1h-indazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C)C(C(NC4=CC=3)=O)C)=NNC2=C1 ZGXRKIVHNAJFGW-UHFFFAOYSA-N 0.000 claims description 3
- LZDIGLUPIQGJDJ-UHFFFAOYSA-N 6-[2-[4-(1h-indazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(C(NC4=CC=3)=O)C)=NNC2=C1 LZDIGLUPIQGJDJ-UHFFFAOYSA-N 0.000 claims description 3
- KAMICTPYNGFHKY-UHFFFAOYSA-N 6-[2-[4-(1h-indazol-3-yl)piperazin-1-yl]ethyl]-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(=O)CC(C4=C3)(C)C)=NNC2=C1 KAMICTPYNGFHKY-UHFFFAOYSA-N 0.000 claims description 3
- JHBMJIYNOSDZEY-UHFFFAOYSA-N 6-[2-[4-(1h-indazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(=O)CC(C4=C3)C)=NNC2=C1 JHBMJIYNOSDZEY-UHFFFAOYSA-N 0.000 claims description 3
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims description 3
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 208000022610 schizoaffective disease Diseases 0.000 claims description 3
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical group FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- VVADVVFTGWEULM-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1,3,3,4,4-pentamethylquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)C(C)(C)C(=O)N(C4=CC=3)C)=NSC2=C1 VVADVVFTGWEULM-UHFFFAOYSA-N 0.000 claims 1
- MSJQLONJZSHSSW-UHFFFAOYSA-N 6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-1,3,3,4,4-pentamethylquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)C(C)(C)C(=O)N(C4=CC=3)C)=NOC2=C1 MSJQLONJZSHSSW-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 150000002431 hydrogen Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 216
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 174
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 147
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 123
- 239000007787 solid Substances 0.000 description 118
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 113
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 106
- 238000005160 1H NMR spectroscopy Methods 0.000 description 105
- 235000019439 ethyl acetate Nutrition 0.000 description 87
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 80
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 71
- 239000000203 mixture Substances 0.000 description 66
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 60
- 239000011541 reaction mixture Substances 0.000 description 60
- 239000000243 solution Substances 0.000 description 59
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 53
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 52
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 48
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 45
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 44
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 39
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 38
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 35
- 239000000047 product Substances 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 32
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 30
- 239000002244 precipitate Substances 0.000 description 30
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 30
- 239000003921 oil Substances 0.000 description 28
- 235000019198 oils Nutrition 0.000 description 28
- DOQLJTKEUIJSKK-UHFFFAOYSA-N 3-piperazin-1-yl-1,2-benzothiazole;hydrochloride Chemical compound Cl.C1CNCCN1C1=NSC2=CC=CC=C12 DOQLJTKEUIJSKK-UHFFFAOYSA-N 0.000 description 27
- 229910000027 potassium carbonate Inorganic materials 0.000 description 26
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- 238000004809 thin layer chromatography Methods 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- 235000011181 potassium carbonates Nutrition 0.000 description 23
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 22
- 235000019341 magnesium sulphate Nutrition 0.000 description 22
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 22
- 239000002904 solvent Substances 0.000 description 22
- 238000003818 flash chromatography Methods 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 19
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 19
- 239000002245 particle Substances 0.000 description 19
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Inorganic materials [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 19
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 238000010992 reflux Methods 0.000 description 18
- 238000003756 stirring Methods 0.000 description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- 239000012043 crude product Substances 0.000 description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 15
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- QSXYQRWLEGCKEW-UHFFFAOYSA-N 3-piperazin-1-yl-1,2-benzoxazole;hydrochloride Chemical compound Cl.C1CNCCN1C1=NOC2=CC=CC=C12 QSXYQRWLEGCKEW-UHFFFAOYSA-N 0.000 description 12
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 12
- 229910052938 sodium sulfate Inorganic materials 0.000 description 12
- 235000011152 sodium sulphate Nutrition 0.000 description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- ZDFQBFVFCPABKQ-UHFFFAOYSA-N 3-piperazin-1-yl-1,2-benzoxazole Chemical compound C1CNCCN1C1=NOC2=CC=CC=C12 ZDFQBFVFCPABKQ-UHFFFAOYSA-N 0.000 description 10
- 238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- 230000003287 optical effect Effects 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 9
- INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 9
- OINXHEDREXQARV-UHFFFAOYSA-N 3-piperazin-1-yl-1h-indazole;hydrochloride Chemical compound Cl.C1CNCCN1C1=NNC2=CC=CC=C12 OINXHEDREXQARV-UHFFFAOYSA-N 0.000 description 8
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 8
- OSPQSTVUFAJUFL-UHFFFAOYSA-N 6-(3-chloropropyl)-3,3-dimethyl-1,4-dihydroquinolin-2-one Chemical compound ClCCCC1=CC=C2NC(=O)C(C)(C)CC2=C1 OSPQSTVUFAJUFL-UHFFFAOYSA-N 0.000 description 8
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000005457 ice water Substances 0.000 description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 description 8
- 229910000104 sodium hydride Inorganic materials 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- BDUBTLFQHNYXPC-UHFFFAOYSA-N 3-methylbut-2-enoyl chloride Chemical compound CC(C)=CC(Cl)=O BDUBTLFQHNYXPC-UHFFFAOYSA-N 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 230000014759 maintenance of location Effects 0.000 description 7
- 229940098779 methanesulfonic acid Drugs 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 235000009518 sodium iodide Nutrition 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- FIUPUXVUJXEVEU-UHFFFAOYSA-N 6-(3-chloropropyl)-3-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound ClCCCC1=CC=C2NC(=O)C(C)CC2=C1 FIUPUXVUJXEVEU-UHFFFAOYSA-N 0.000 description 6
- DLUZDQGRMGTVMF-UHFFFAOYSA-N 6-(3-chloropropyl)-4-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=C(CCCCl)C=C2C(C)CC(=O)NC2=C1 DLUZDQGRMGTVMF-UHFFFAOYSA-N 0.000 description 6
- KOEMHSHNEOWGOD-UHFFFAOYSA-N 6-(3-chloropropyl)-7-fluoro-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound FC1=C(CCCCl)C=C2C(C)(C)CC(=O)NC2=C1 KOEMHSHNEOWGOD-UHFFFAOYSA-N 0.000 description 6
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
- 239000007832 Na2SO4 Substances 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 150000001557 benzodiazepines Chemical class 0.000 description 6
- 239000012458 free base Substances 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- 239000010502 orange oil Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 229920000137 polyphosphoric acid Polymers 0.000 description 6
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 6
- 235000017550 sodium carbonate Nutrition 0.000 description 6
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 5
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 description 5
- PMLVHJJSMRAEMM-UHFFFAOYSA-N 6-(3-chloropropyl)-4,4,8-trimethyl-1,3-dihydroquinolin-2-one Chemical compound N1C(=O)CC(C)(C)C2=C1C(C)=CC(CCCCl)=C2 PMLVHJJSMRAEMM-UHFFFAOYSA-N 0.000 description 5
- DNDUNUIFAOEGAN-UHFFFAOYSA-N 6-(3-chloropropyl)-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound C1=C(CCCCl)C=C2C(C)(C)CC(=O)NC2=C1 DNDUNUIFAOEGAN-UHFFFAOYSA-N 0.000 description 5
- WKFUSWCXAAWXEI-UHFFFAOYSA-N 6-(3-chloropropyl)-8-ethyl-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound N1C(=O)CC(C)(C)C2=C1C(CC)=CC(CCCCl)=C2 WKFUSWCXAAWXEI-UHFFFAOYSA-N 0.000 description 5
- BYSNTGXPBJWZNO-UHFFFAOYSA-N 7-chloro-6-(3-chloropropyl)-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound ClC1=C(CCCCl)C=C2C(C)(C)CC(=O)NC2=C1 BYSNTGXPBJWZNO-UHFFFAOYSA-N 0.000 description 5
- QVJJQPMAYKAZDE-UHFFFAOYSA-N 8-chloro-6-(3-chloropropyl)-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound C1=C(CCCCl)C=C2C(C)(C)CC(=O)NC2=C1Cl QVJJQPMAYKAZDE-UHFFFAOYSA-N 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 5
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 5
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 5
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 5
- 235000019502 Orange oil Nutrition 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 150000007514 bases Chemical class 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 125000004494 ethyl ester group Chemical group 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 229940044551 receptor antagonist Drugs 0.000 description 5
- 239000002464 receptor antagonist Substances 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- KAENAPPKGHXOII-UHFFFAOYSA-N 1-[6-(3-chloropropyl)-3,3-dimethyl-2,4-dihydroquinolin-1-yl]ethanone Chemical compound ClCCCC1=CC=C2N(C(=O)C)CC(C)(C)CC2=C1 KAENAPPKGHXOII-UHFFFAOYSA-N 0.000 description 4
- YUXVDJIECWCUJV-UHFFFAOYSA-N 1-[6-(3-chloropropyl)-4,4-dimethyl-2,3-dihydroquinolin-1-yl]ethanone Chemical compound ClCCCC1=CC=C2N(C(=O)C)CCC(C)(C)C2=C1 YUXVDJIECWCUJV-UHFFFAOYSA-N 0.000 description 4
- XNRWRTHYBUMIIR-UHFFFAOYSA-N 1-[6-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-3,3-dimethyl-2,4-dihydroquinolin-1-yl]ethanone Chemical compound C1=CC=C2C(N3CCN(CC3)CCCC=3C=C4CC(C)(C)CN(C4=CC=3)C(=O)C)=NSC2=C1 XNRWRTHYBUMIIR-UHFFFAOYSA-N 0.000 description 4
- AQVSHTVJZFSLCG-UHFFFAOYSA-N 1-[6-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-4,4-dimethyl-2,3-dihydroquinolin-1-yl]ethanone Chemical compound C1=CC=C2C(N3CCN(CC3)CCCC=3C=C4C(C)(C)CCN(C4=CC=3)C(=O)C)=NSC2=C1 AQVSHTVJZFSLCG-UHFFFAOYSA-N 0.000 description 4
- VNOWFIKPZWPEDR-UHFFFAOYSA-N 1-[6-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-7-fluoro-4,4-dimethyl-2,3-dihydroquinolin-1-yl]ethanone Chemical compound C1=CC=C2C(N3CCN(CC3)CCCC=3C=C4C(C)(C)CCN(C4=CC=3F)C(=O)C)=NSC2=C1 VNOWFIKPZWPEDR-UHFFFAOYSA-N 0.000 description 4
- PMRPHYURHJMNPK-UHFFFAOYSA-N 3-[4-[3-(1,3,3-trimethyl-2,4-dihydroquinolin-6-yl)propyl]piperazin-1-yl]-1,2-benzothiazole Chemical compound C1=CC=C2C(N3CCN(CC3)CCCC=3C=C4CC(C)(C)CN(C4=CC=3)C)=NSC2=C1 PMRPHYURHJMNPK-UHFFFAOYSA-N 0.000 description 4
- YLYLUXSYFLHKAR-UHFFFAOYSA-N 6-(3-chloropropanoyl)-3,3-dimethyl-1,4-dihydroquinolin-2-one Chemical compound ClCCC(=O)C1=CC=C2NC(=O)C(C)(C)CC2=C1 YLYLUXSYFLHKAR-UHFFFAOYSA-N 0.000 description 4
- ZTERYTAFNJHOTF-UHFFFAOYSA-N 6-(3-chloropropanoyl)-3-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound ClCCC(=O)C1=CC=C2NC(=O)C(C)CC2=C1 ZTERYTAFNJHOTF-UHFFFAOYSA-N 0.000 description 4
- FXLVOQCQVQRCRY-UHFFFAOYSA-N 6-(3-chloropropanoyl)-4,4,8-trimethyl-1,3-dihydroquinolin-2-one Chemical compound N1C(=O)CC(C)(C)C2=C1C(C)=CC(C(=O)CCCl)=C2 FXLVOQCQVQRCRY-UHFFFAOYSA-N 0.000 description 4
- BKPVTCXAQMVQDR-UHFFFAOYSA-N 6-(3-chloropropanoyl)-4-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=C(C(=O)CCCl)C=C2C(C)CC(=O)NC2=C1 BKPVTCXAQMVQDR-UHFFFAOYSA-N 0.000 description 4
- LEDVDEXNXCLPEY-UHFFFAOYSA-N 6-(3-chloropropanoyl)-7-fluoro-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound FC1=C(C(=O)CCCl)C=C2C(C)(C)CC(=O)NC2=C1 LEDVDEXNXCLPEY-UHFFFAOYSA-N 0.000 description 4
- LUVRRFOTRRLZRT-UHFFFAOYSA-N 6-(3-chloropropanoyl)-8-ethyl-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound N1C(=O)CC(C)(C)C2=C1C(CC)=CC(C(=O)CCCl)=C2 LUVRRFOTRRLZRT-UHFFFAOYSA-N 0.000 description 4
- UMIKPJSTKGIJAZ-UHFFFAOYSA-N 6-(3-chloropropyl)-1,3,3-trimethyl-2,4-dihydroquinoline Chemical compound ClCCCC1=CC=C2N(C)CC(C)(C)CC2=C1 UMIKPJSTKGIJAZ-UHFFFAOYSA-N 0.000 description 4
- WPGCDUNSTSNMKK-UHFFFAOYSA-N 6-(3-chloropropyl)-3,3-dimethyl-2,4-dihydro-1h-quinoline Chemical compound C1=C(CCCCl)C=C2CC(C)(C)CNC2=C1 WPGCDUNSTSNMKK-UHFFFAOYSA-N 0.000 description 4
- BBPLZXPSPPAYFV-UHFFFAOYSA-N 6-(3-chloropropyl)-4,4-dimethyl-2,3-dihydro-1h-quinoline Chemical compound C1=C(CCCCl)C=C2C(C)(C)CCNC2=C1 BBPLZXPSPPAYFV-UHFFFAOYSA-N 0.000 description 4
- ODBQLTRMOAIGFM-UHFFFAOYSA-N 6-[2-[4-(5-fluoro-1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1h-quinolin-2-one Chemical compound C1=C(F)C=C2C(N3CCN(CC3)CCC3=CC=C4NC(=O)C(C)=C(C4=C3)C)=NOC2=C1 ODBQLTRMOAIGFM-UHFFFAOYSA-N 0.000 description 4
- QXBUKWMIVHOCMC-UHFFFAOYSA-N 6-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-4,4,8-trimethyl-1,3-dihydroquinolin-2-one Chemical compound N1C(=O)CC(C)(C)C2=C1C(C)=CC(CCCN1CCN(CC1)C=1C3=CC=CC=C3SN=1)=C2 QXBUKWMIVHOCMC-UHFFFAOYSA-N 0.000 description 4
- WHSOWNGVSFCCRZ-UHFFFAOYSA-N 6-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-7-fluoro-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCCC3=C(F)C=C4NC(=O)CC(C4=C3)(C)C)=NSC2=C1 WHSOWNGVSFCCRZ-UHFFFAOYSA-N 0.000 description 4
- VLTVIYDRNUHTPJ-UHFFFAOYSA-N 6-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-8-chloro-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCCC3=CC(Cl)=C4NC(=O)CC(C4=C3)(C)C)=NSC2=C1 VLTVIYDRNUHTPJ-UHFFFAOYSA-N 0.000 description 4
- IIUWIHCFIFDWJD-UHFFFAOYSA-N 6-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-8-ethyl-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound N1C(=O)CC(C)(C)C2=C1C(CC)=CC(CCCN1CCN(CC1)C=1C3=CC=CC=C3SN=1)=C2 IIUWIHCFIFDWJD-UHFFFAOYSA-N 0.000 description 4
- ZHUQMHPWELTVGK-UHFFFAOYSA-N 7-chloro-6-(3-chloropropanoyl)-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound ClC1=C(C(=O)CCCl)C=C2C(C)(C)CC(=O)NC2=C1 ZHUQMHPWELTVGK-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000002841 Lewis acid Substances 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 150000007517 lewis acids Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 4
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- UOYNXQYJKMLTGN-MRVPVSSYSA-N (4r)-6-(2-chloroethyl)-4-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=C(CCCl)C=C2[C@H](C)CC(=O)NC2=C1 UOYNXQYJKMLTGN-MRVPVSSYSA-N 0.000 description 3
- WJMJAABZHXLYBK-QGZVFWFLSA-N (4r)-6-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-4-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCCC3=CC=C4NC(=O)C[C@H](C4=C3)C)=NSC2=C1 WJMJAABZHXLYBK-QGZVFWFLSA-N 0.000 description 3
- PSKPYRZXGUASSX-QGZVFWFLSA-N (4r)-6-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-4-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCCC3=CC=C4NC(=O)C[C@H](C4=C3)C)=NOC2=C1 PSKPYRZXGUASSX-QGZVFWFLSA-N 0.000 description 3
- DLYORQYHSOYMRD-UHFFFAOYSA-N 1-[6-(3-chloropropyl)-7-fluoro-4,4-dimethyl-2,3-dihydroquinolin-1-yl]ethanone Chemical compound ClCCCC1=C(F)C=C2N(C(=O)C)CCC(C)(C)C2=C1 DLYORQYHSOYMRD-UHFFFAOYSA-N 0.000 description 3
- GTTFYSJDNZFRLZ-UHFFFAOYSA-N 4-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2C(C)CC(=O)NC2=C1 GTTFYSJDNZFRLZ-UHFFFAOYSA-N 0.000 description 3
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 3
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 3
- OMGCOZVZFLZUAA-UHFFFAOYSA-N 6-(2-chloroacetyl)-4,4,8-trimethyl-1,3-dihydroquinolin-2-one Chemical compound N1C(=O)CC(C)(C)C2=C1C(C)=CC(C(=O)CCl)=C2 OMGCOZVZFLZUAA-UHFFFAOYSA-N 0.000 description 3
- WIEICMKFPDERGT-UHFFFAOYSA-N 6-(2-chloroethyl)-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound C1=C(CCCl)C=C2C(C)(C)CC(=O)NC2=C1 WIEICMKFPDERGT-UHFFFAOYSA-N 0.000 description 3
- YZTJTHMWNLFXDC-UHFFFAOYSA-N 6-(3-chloropropanoyl)-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound C1=C(C(=O)CCCl)C=C2C(C)(C)CC(=O)NC2=C1 YZTJTHMWNLFXDC-UHFFFAOYSA-N 0.000 description 3
- JVUGDLYWOHTQPF-UHFFFAOYSA-N 6-(3-chloropropyl)-7-fluoro-1,4,4-trimethyl-3h-quinolin-2-one Chemical compound ClCCCC1=C(F)C=C2N(C)C(=O)CC(C)(C)C2=C1 JVUGDLYWOHTQPF-UHFFFAOYSA-N 0.000 description 3
- JTIDQNXKSWEQMD-UHFFFAOYSA-N 6-(3-chloropropyl)-7-fluoro-4,4-dimethyl-2,3-dihydro-1h-quinoline Chemical compound FC1=C(CCCCl)C=C2C(C)(C)CCNC2=C1 JTIDQNXKSWEQMD-UHFFFAOYSA-N 0.000 description 3
- IRVXRGBZROFABT-UHFFFAOYSA-N 6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(=O)C(C)=C(C4=C3)C)=NOC2=C1 IRVXRGBZROFABT-UHFFFAOYSA-N 0.000 description 3
- ICJOYQPAZXCVRB-UHFFFAOYSA-N 6-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCCC3=CC=C4NC(=O)CC(C4=C3)(C)C)=NSC2=C1 ICJOYQPAZXCVRB-UHFFFAOYSA-N 0.000 description 3
- YIGLLMOGZFXREZ-UHFFFAOYSA-N 6-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-7-fluoro-1,4,4-trimethyl-3h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCCC=3C=C4C(C)(C)CC(=O)N(C4=CC=3F)C)=NSC2=C1 YIGLLMOGZFXREZ-UHFFFAOYSA-N 0.000 description 3
- QJSVLJVCMAYLDS-UHFFFAOYSA-N 6-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-4,4,8-trimethyl-1,3-dihydroquinolin-2-one Chemical compound N1C(=O)CC(C)(C)C2=C1C(C)=CC(CCCN1CCN(CC1)C=1C3=CC=CC=C3ON=1)=C2 QJSVLJVCMAYLDS-UHFFFAOYSA-N 0.000 description 3
- RCJPQFCBEXJUMP-UHFFFAOYSA-N 8-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1,2,3,5-tetrahydrocyclopenta[c]quinolin-4-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(C=5CCCC=5C4=C3)=O)=NSC2=C1 RCJPQFCBEXJUMP-UHFFFAOYSA-N 0.000 description 3
- RBNSGWXAZWAUME-UHFFFAOYSA-N 8-chloro-6-(3-chloropropanoyl)-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound C1=C(C(=O)CCCl)C=C2C(C)(C)CC(=O)NC2=C1Cl RBNSGWXAZWAUME-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000004296 chiral HPLC Methods 0.000 description 3
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 3
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 229940080818 propionamide Drugs 0.000 description 3
- 239000002287 radioligand Substances 0.000 description 3
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 3
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- DLUZDQGRMGTVMF-SECBINFHSA-N (4r)-6-(3-chloropropyl)-4-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=C(CCCCl)C=C2[C@H](C)CC(=O)NC2=C1 DLUZDQGRMGTVMF-SECBINFHSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical class C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 2
- AGMROOFWCSZNJU-UHFFFAOYSA-N 1,4,7-trioxaspiro[4.4]nonane-9-carboxylic acid Chemical compound OC(=O)C1COCC11OCCO1 AGMROOFWCSZNJU-UHFFFAOYSA-N 0.000 description 2
- OUQVHXULOKQCLX-UHFFFAOYSA-N 1-(1-benzothiophen-3-yl)piperazine;hydrochloride Chemical compound Cl.C1CNCCN1C1=CSC2=CC=CC=C12 OUQVHXULOKQCLX-UHFFFAOYSA-N 0.000 description 2
- RIYCELWTKCAMCO-UHFFFAOYSA-N 1-(6-fluoro-1-benzothiophen-3-yl)piperazine;hydrochloride Chemical compound Cl.C=1SC2=CC(F)=CC=C2C=1N1CCNCC1 RIYCELWTKCAMCO-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical compound NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 description 2
- MLPVBIWIRCKMJV-UHFFFAOYSA-N 2-ethylaniline Chemical compound CCC1=CC=CC=C1N MLPVBIWIRCKMJV-UHFFFAOYSA-N 0.000 description 2
- OTASHKSOGHDFJE-UHFFFAOYSA-N 3,3-dimethyl-1,4-dihydroquinolin-2-one Chemical compound C1=CC=C2NC(=O)C(C)(C)CC2=C1 OTASHKSOGHDFJE-UHFFFAOYSA-N 0.000 description 2
- ZUVPLKVDZNDZCM-UHFFFAOYSA-N 3-chloro-2-methylaniline Chemical compound CC1=C(N)C=CC=C1Cl ZUVPLKVDZNDZCM-UHFFFAOYSA-N 0.000 description 2
- DBWYGOJLDBJJLU-UHFFFAOYSA-N 3-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2NC(=O)C(C)CC2=C1 DBWYGOJLDBJJLU-UHFFFAOYSA-N 0.000 description 2
- YYPNJNDODFVZLE-UHFFFAOYSA-N 3-methylbut-2-enoic acid Chemical compound CC(C)=CC(O)=O YYPNJNDODFVZLE-UHFFFAOYSA-N 0.000 description 2
- LLIIGIZPLMNHEA-UHFFFAOYSA-N 4,4,8-trimethyl-1,3-dihydroquinolin-2-one Chemical compound N1C(=O)CC(C)(C)C2=C1C(C)=CC=C2 LLIIGIZPLMNHEA-UHFFFAOYSA-N 0.000 description 2
- HMOBRUPKXAKFHS-UHFFFAOYSA-N 4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound C1=CC=C2C(C)(C)CC(=O)NC2=C1 HMOBRUPKXAKFHS-UHFFFAOYSA-N 0.000 description 2
- RPAPXEDQFIMNLB-UHFFFAOYSA-N 4-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]aniline Chemical compound C1=CC(N)=CC=C1CCN1CCN(C=2C3=CC=CC=C3SN=2)CC1 RPAPXEDQFIMNLB-UHFFFAOYSA-N 0.000 description 2
- YOCQGLAPIWFPNG-UHFFFAOYSA-N 4-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]aniline Chemical compound C1=CC(N)=CC=C1CCCN1CCN(C=2C3=CC=CC=C3SN=2)CC1 YOCQGLAPIWFPNG-UHFFFAOYSA-N 0.000 description 2
- ZNBKITPHCCSAHX-UHFFFAOYSA-N 5-chloro-3-piperazin-1-yl-1,2-benzoxazole Chemical compound C12=CC(Cl)=CC=C2ON=C1N1CCNCC1 ZNBKITPHCCSAHX-UHFFFAOYSA-N 0.000 description 2
- NPVCHWDBLSZUSM-UHFFFAOYSA-N 5-fluoro-3-piperazin-1-yl-1,2-benzothiazole Chemical compound C12=CC(F)=CC=C2SN=C1N1CCNCC1 NPVCHWDBLSZUSM-UHFFFAOYSA-N 0.000 description 2
- QQNJGROQNZOJGG-UHFFFAOYSA-N 5-fluoro-3-piperazin-1-yl-1,2-benzoxazole Chemical compound C12=CC(F)=CC=C2ON=C1N1CCNCC1 QQNJGROQNZOJGG-UHFFFAOYSA-N 0.000 description 2
- TVNQMQCIFJAEOP-UHFFFAOYSA-N 6-(2-chloroacetyl)-7-fluoro-4,4,8-trimethyl-1,3-dihydroquinolin-2-one Chemical compound N1C(=O)CC(C)(C)C2=C1C(C)=C(F)C(C(=O)CCl)=C2 TVNQMQCIFJAEOP-UHFFFAOYSA-N 0.000 description 2
- HFVYWHDYYYZNSS-UHFFFAOYSA-N 6-(2-chloroethyl)-4,4,8-trimethyl-1,3-dihydroquinolin-2-one Chemical compound N1C(=O)CC(C)(C)C2=C1C(C)=CC(CCCl)=C2 HFVYWHDYYYZNSS-UHFFFAOYSA-N 0.000 description 2
- IFOMETMAHWNOHE-UHFFFAOYSA-N 6-(2-chloroethyl)-7-fluoro-4,4,8-trimethyl-1,3-dihydroquinolin-2-one Chemical compound N1C(=O)CC(C)(C)C2=C1C(C)=C(F)C(CCCl)=C2 IFOMETMAHWNOHE-UHFFFAOYSA-N 0.000 description 2
- ACNPNTCEXDHNCN-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(=O)C(C)=C(C4=C3)C)=NSC2=C1 ACNPNTCEXDHNCN-UHFFFAOYSA-N 0.000 description 2
- GYHWKJPKRYBSGV-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(C(NC4=CC=3)=O)C)=NSC2=C1 GYHWKJPKRYBSGV-UHFFFAOYSA-N 0.000 description 2
- PYCCZBHPGGXRCA-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-7-fluoro-4,4,8-trimethyl-1,3-dihydroquinolin-2-one methanesulfonic acid Chemical compound CS(=O)(=O)O.S1N=C(C2=C1C=CC=C2)N2CCN(CC2)CCC=2C=C1C(CC(NC1=C(C2F)C)=O)(C)C PYCCZBHPGGXRCA-UHFFFAOYSA-N 0.000 description 2
- NPMULJKKBNCCDE-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-8-chloro-4,4-dimethyl-1,3-dihydroquinolin-2-one;hydrochloride Chemical compound Cl.C1=CC=C2C(N3CCN(CC3)CCC3=CC(Cl)=C4NC(=O)CC(C4=C3)(C)C)=NSC2=C1 NPMULJKKBNCCDE-UHFFFAOYSA-N 0.000 description 2
- XYEBUQCMQVMBKK-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-8-ethyl-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound N1C(=O)CC(C)(C)C2=C1C(CC)=CC(CCN1CCN(CC1)C=1C3=CC=CC=C3SN=1)=C2 XYEBUQCMQVMBKK-UHFFFAOYSA-N 0.000 description 2
- NUOHQYYWPOCRKS-UHFFFAOYSA-N 6-[2-[4-(5-chloro-1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1h-quinolin-2-one Chemical compound C1=C(Cl)C=C2C(N3CCN(CC3)CCC3=CC=C4NC(=O)C(C)=C(C4=C3)C)=NOC2=C1 NUOHQYYWPOCRKS-UHFFFAOYSA-N 0.000 description 2
- WGSOGKCSTBOKEB-UHFFFAOYSA-N 6-[2-[4-(5-fluoro-1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1h-quinolin-2-one Chemical compound C1=C(F)C=C2C(N3CCN(CC3)CCC3=CC=C4NC(=O)C(C)=C(C4=C3)C)=NSC2=C1 WGSOGKCSTBOKEB-UHFFFAOYSA-N 0.000 description 2
- MJUBWXJYPULCOR-UHFFFAOYSA-N 6-[2-[4-(5-fluoro-1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-1,3-dihydroquinolin-2-one Chemical compound N1C(=O)CC(C)(C)C2=C1C(C)=CC(CCN1CCN(CC1)C=1C3=CC(F)=CC=C3SN=1)=C2 MJUBWXJYPULCOR-UHFFFAOYSA-N 0.000 description 2
- DMNNHBQPYPVDCP-UHFFFAOYSA-N 6-[2-[4-(5-methoxy-1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1h-quinolin-2-one Chemical compound N1C(=O)C(C)=C(C)C2=CC(CCN3CCN(CC3)C3=NSC4=CC=C(C=C43)OC)=CC=C21 DMNNHBQPYPVDCP-UHFFFAOYSA-N 0.000 description 2
- HZAPEJZVGGKJBI-UHFFFAOYSA-N 6-[2-[4-(6-fluoro-1,2-benzothiazol-3-yl)piperidin-1-yl]ethyl]-3,4-dimethyl-1h-quinolin-2-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC3=CC=C4NC(=O)C(C)=C(C4=C3)C)=NSC2=C1 HZAPEJZVGGKJBI-UHFFFAOYSA-N 0.000 description 2
- RUKAGDACVIGXPH-UHFFFAOYSA-N 6-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1h-quinolin-2-one Chemical compound FC1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(=O)C(C)=C(C4=C3)C)=NOC2=C1 RUKAGDACVIGXPH-UHFFFAOYSA-N 0.000 description 2
- FMLHSMXZZWKMJT-UHFFFAOYSA-N 6-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-3,4-dimethyl-1h-quinolin-2-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC3=CC=C4NC(=O)C(C)=C(C4=C3)C)=NOC2=C1 FMLHSMXZZWKMJT-UHFFFAOYSA-N 0.000 description 2
- GCTBAMIHYYQWKY-UHFFFAOYSA-N 6-[2-[4-(7-fluoro-1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(=O)C(C)=C(C4=C3)C)=NSC2=C1F GCTBAMIHYYQWKY-UHFFFAOYSA-N 0.000 description 2
- RNKQDXFWZDRSEG-UHFFFAOYSA-N 6-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-8-chloro-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCCC3=CC(Cl)=C4NC(=O)CC(C4=C3)(C)C)=NOC2=C1 RNKQDXFWZDRSEG-UHFFFAOYSA-N 0.000 description 2
- FDXYUNUMYBEUAY-UHFFFAOYSA-N 6-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-8-ethyl-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound N1C(=O)CC(C)(C)C2=C1C(CC)=CC(CCCN1CCN(CC1)C=1C3=CC=CC=C3ON=1)=C2 FDXYUNUMYBEUAY-UHFFFAOYSA-N 0.000 description 2
- HIJIRWINRTWZMT-UHFFFAOYSA-N 6-fluoro-3-piperazin-1-yl-1,2-benzothiazole Chemical compound N=1SC2=CC(F)=CC=C2C=1N1CCNCC1 HIJIRWINRTWZMT-UHFFFAOYSA-N 0.000 description 2
- CZIQFAZBYIAMCS-UHFFFAOYSA-N 6-fluoro-3-piperidin-4-yl-1,2-benzothiazole;hydrochloride Chemical compound Cl.N=1SC2=CC(F)=CC=C2C=1C1CCNCC1 CZIQFAZBYIAMCS-UHFFFAOYSA-N 0.000 description 2
- CWPSRUREOSBKBQ-UHFFFAOYSA-N 6-fluoro-3-piperidin-4-yl-1,2-benzoxazole;hydrochloride Chemical compound Cl.N=1OC2=CC(F)=CC=C2C=1C1CCNCC1 CWPSRUREOSBKBQ-UHFFFAOYSA-N 0.000 description 2
- VPRBRDKDSDZLJE-UHFFFAOYSA-N 7-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-4,4-dimethyl-1-azatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CCCN5C(=O)CC(C(C=3)=C54)(C)C)=NSC2=C1 VPRBRDKDSDZLJE-UHFFFAOYSA-N 0.000 description 2
- BPFMPSLVYDAGEW-UHFFFAOYSA-N 8-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-2-methyl-3,5-dihydro-1h-pyrrolo[3,4-c]quinolin-4-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(=O)C5=C(C4=C3)CN(C5)C)=NSC2=C1 BPFMPSLVYDAGEW-UHFFFAOYSA-N 0.000 description 2
- YEKGFIORXFPUMW-UHFFFAOYSA-N 8-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-5-ethyl-2,3-dihydro-1h-cyclopenta[c]quinolin-4-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4N(C(C=5CCCC=5C4=C3)=O)CC)=NSC2=C1 YEKGFIORXFPUMW-UHFFFAOYSA-N 0.000 description 2
- COPIDZGQPCGIIS-UHFFFAOYSA-N 8-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-methyl-3,5-dihydro-1h-furo[3,4-c]quinolin-4-one Chemical compound C1=2COCC=2C(=O)NC2=C1C=C(CCN1CCN(CC1)C=1C3=CC=CC=C3SN=1)C=C2C COPIDZGQPCGIIS-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- DKDXVAZEBXCVKQ-UHFFFAOYSA-N 8-chloro-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound C1=CC=C2C(C)(C)CC(=O)NC2=C1Cl DKDXVAZEBXCVKQ-UHFFFAOYSA-N 0.000 description 2
- UDXJCJCLUXVAON-UHFFFAOYSA-N 8-ethyl-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound N1C(=O)CC(C)(C)C2=C1C(CC)=CC=C2 UDXJCJCLUXVAON-UHFFFAOYSA-N 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 2
- 206010003805 Autism Diseases 0.000 description 2
- 229910015900 BF3 Inorganic materials 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 101100240517 Caenorhabditis elegans nhr-11 gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 2
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- 208000012202 Pervasive developmental disease Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 201000009916 Postpartum depression Diseases 0.000 description 2
- 208000020186 Schizophreniform disease Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 102100037346 Substance-P receptor Human genes 0.000 description 2
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 2
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000029560 autism spectrum disease Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- IVJSUVIAMVNGNO-UHFFFAOYSA-N ethyl 2-[[3-[4-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]anilino]-3-oxopropyl]-methylamino]acetate Chemical compound C1=CC(NC(=O)CCN(C)CC(=O)OCC)=CC=C1CCCN1CCN(C=2C3=CC=CC=C3SN=2)CC1 IVJSUVIAMVNGNO-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- UPWPDUACHOATKO-UHFFFAOYSA-K gallium trichloride Chemical compound Cl[Ga](Cl)Cl UPWPDUACHOATKO-UHFFFAOYSA-K 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000008241 heterogeneous mixture Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- SHLZBPXZIKYSQV-UHFFFAOYSA-N n-[4-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]phenyl]-1-methyl-4-oxopyrrolidine-3-carboxamide Chemical compound O=C1CN(C)CC1C(=O)NC(C=C1)=CC=C1CCCN1CCN(C=2C3=CC=CC=C3SN=2)CC1 SHLZBPXZIKYSQV-UHFFFAOYSA-N 0.000 description 2
- XBPPYOQHCUUJKS-UHFFFAOYSA-N n-[4-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]phenyl]prop-2-enamide Chemical compound C1=CC(NC(=O)C=C)=CC=C1CCCN1CCN(C=2C3=CC=CC=C3SN=2)CC1 XBPPYOQHCUUJKS-UHFFFAOYSA-N 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- RNVCVTLRINQCPJ-UHFFFAOYSA-N o-toluidine Chemical compound CC1=CC=CC=C1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- VLCMRTMCMQJSKM-UHFFFAOYSA-N phenyl-[4-phenyl-8-(trifluoromethyl)quinolin-3-yl]methanone Chemical compound C=1C=CC=CC=1C(=O)C1=CN=C2C(C(F)(F)F)=CC=CC2=C1C1=CC=CC=C1 VLCMRTMCMQJSKM-UHFFFAOYSA-N 0.000 description 2
- 208000019899 phobic disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 229930185107 quinolinone Natural products 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000004001 serotonin 1D antagonist Substances 0.000 description 2
- 229960002073 sertraline Drugs 0.000 description 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 201000009032 substance abuse Diseases 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- PUGUQINMNYINPK-UHFFFAOYSA-N tert-butyl 4-(2-chloroacetyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(C(=O)CCl)CC1 PUGUQINMNYINPK-UHFFFAOYSA-N 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- DUNKXUFBGCUVQW-UHFFFAOYSA-J zirconium tetrachloride Chemical compound Cl[Zr](Cl)(Cl)Cl DUNKXUFBGCUVQW-UHFFFAOYSA-J 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- VWSNFHTUMWMGBG-QGZVFWFLSA-N (4r)-6-[2-[4-(1-benzothiophen-3-yl)piperazin-1-yl]ethyl]-4-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(=O)C[C@H](C4=C3)C)=CSC2=C1 VWSNFHTUMWMGBG-QGZVFWFLSA-N 0.000 description 1
- RJXPUAUIGRGCHC-MRXNPFEDSA-N (4r)-6-[2-[4-(6-fluoro-1-benzothiophen-3-yl)piperazin-1-yl]ethyl]-4-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound FC1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(=O)C[C@H](C4=C3)C)=CSC2=C1 RJXPUAUIGRGCHC-MRXNPFEDSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- TZJUVVIWVWFLCD-UHFFFAOYSA-N 1,1-dioxo-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzothiazol-3-one Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 TZJUVVIWVWFLCD-UHFFFAOYSA-N 0.000 description 1
- FSWDXHLZOVHHGV-UHFFFAOYSA-N 1,2,6,7-tetrahydro-5h-pyrido[3,2,1-ij]quinolin-3-one Chemical compound C1CCN2C(=O)CCC3=CC=CC1=C32 FSWDXHLZOVHHGV-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- ZHQQVANLJMMNGW-UHFFFAOYSA-N 1,3,3,4,4-pentamethylquinolin-2-one Chemical compound C1=CC=C2N(C)C(=O)C(C)(C)C(C)(C)C2=C1 ZHQQVANLJMMNGW-UHFFFAOYSA-N 0.000 description 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
- GVCMFAGYMNVFSA-UHFFFAOYSA-N 1,4,4-trimethyl-3h-quinolin-2-one Chemical compound C1=CC=C2N(C)C(=O)CC(C)(C)C2=C1 GVCMFAGYMNVFSA-UHFFFAOYSA-N 0.000 description 1
- XVCGHEUXKRIBOF-UHFFFAOYSA-N 1,4-dimethyl-3,4-dihydroquinolin-2-one Chemical compound C1=CC=C2C(C)CC(=O)N(C)C2=C1 XVCGHEUXKRIBOF-UHFFFAOYSA-N 0.000 description 1
- JRYSGHYWXXHNRD-UHFFFAOYSA-N 1-(2,3-dihydroindol-1-yl)-3-methylbut-2-en-1-one Chemical compound C1=CC=C2N(C(=O)C=C(C)C)CCC2=C1 JRYSGHYWXXHNRD-UHFFFAOYSA-N 0.000 description 1
- LLDXRZZWHKLVLL-UHFFFAOYSA-N 1-(3,4-dihydro-2h-quinolin-1-yl)-3-methylbut-2-en-1-one Chemical compound C1=CC=C2N(C(=O)C=C(C)C)CCCC2=C1 LLDXRZZWHKLVLL-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- FLJCZSOFJWZQQJ-UHFFFAOYSA-N 1-[6-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-3,3-dimethyl-2,4-dihydroquinolin-1-yl]ethanone;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC=C2C(N3CCN(CC3)CCCC=3C=C4CC(C)(C)CN(C4=CC=3)C(=O)C)=NSC2=C1 FLJCZSOFJWZQQJ-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- JZJWEHDUHQGGGA-UHFFFAOYSA-N 2-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-7,8,9,10-tetrahydro-5h-phenanthridin-6-one Chemical compound C1CCCC2=C1C1=CC(CCN3CCN(CC3)C=3C4=CC=CC=C4SN=3)=CC=C1NC2=O JZJWEHDUHQGGGA-UHFFFAOYSA-N 0.000 description 1
- DWVCYPMAMQVSER-UHFFFAOYSA-N 2-[6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-2-oxo-4h-quinolin-1-yl]acetamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(C(N(CC(N)=O)C4=CC=3)=O)(C)C)=NSC2=C1 DWVCYPMAMQVSER-UHFFFAOYSA-N 0.000 description 1
- VYJPNJXNOBGIER-UHFFFAOYSA-N 2-[6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-2-oxo-3,4-dihydroquinolin-1-yl]-n-phenylpropanamide Chemical compound O=C1C(C)CC2=CC(CCN3CCN(CC3)C=3C4=CC=CC=C4SN=3)=CC=C2N1C(C)C(=O)NC1=CC=CC=C1 VYJPNJXNOBGIER-UHFFFAOYSA-N 0.000 description 1
- NAZUTROFRPQZKQ-UHFFFAOYSA-N 2-[6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-2-oxo-3,4-dihydroquinolin-1-yl]propanenitrile Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(C)C(=O)N(C4=CC=3)C(C#N)C)=NSC2=C1 NAZUTROFRPQZKQ-UHFFFAOYSA-N 0.000 description 1
- GUSHXOJOWKDNKV-UHFFFAOYSA-N 2-[6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-2-oxo-3,4-dihydroquinolin-1-yl]-n-phenylpropanamide Chemical compound O=C1CC(C)C2=CC(CCN3CCN(CC3)C=3C4=CC=CC=C4SN=3)=CC=C2N1C(C)C(=O)NC1=CC=CC=C1 GUSHXOJOWKDNKV-UHFFFAOYSA-N 0.000 description 1
- ACRADGOAPQCPFI-UHFFFAOYSA-N 2-[6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-2-oxo-3,4-dihydroquinolin-1-yl]propanenitrile Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C)CC(=O)N(C4=CC=3)C(C#N)C)=NSC2=C1 ACRADGOAPQCPFI-UHFFFAOYSA-N 0.000 description 1
- RZEWVPXDEJBPTP-UHFFFAOYSA-N 2-[6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-2-oxoquinolin-1-yl]acetamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4N(CC(N)=O)C(=O)C(C)=C(C4=C3)C)=NOC2=C1 RZEWVPXDEJBPTP-UHFFFAOYSA-N 0.000 description 1
- HGVQQKUQXSUEKM-UHFFFAOYSA-N 2-[6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-2-oxoquinolin-1-yl]propanamide Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4N(C(C(C)=C(C)C4=C3)=O)C(C(N)=O)C)=NOC2=C1 HGVQQKUQXSUEKM-UHFFFAOYSA-N 0.000 description 1
- QXLPHVIMTQGDFC-UHFFFAOYSA-N 2-[6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-2-oxoquinolin-1-yl]propanenitrile Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4N(C(C(C)=C(C)C4=C3)=O)C(C#N)C)=NOC2=C1 QXLPHVIMTQGDFC-UHFFFAOYSA-N 0.000 description 1
- PXPZKXQAWXCWIY-UHFFFAOYSA-N 2-[6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-2-oxo-3,4-dihydroquinolin-1-yl]-n-phenylpropanamide Chemical compound O=C1CC(C)C2=CC(CCN3CCN(CC3)C=3C4=CC=CC=C4ON=3)=CC=C2N1C(C)C(=O)NC1=CC=CC=C1 PXPZKXQAWXCWIY-UHFFFAOYSA-N 0.000 description 1
- HAESZPVRLOMBIW-UHFFFAOYSA-N 2-[6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-2-oxo-3,4-dihydroquinolin-1-yl]propanenitrile Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C)CC(=O)N(C4=CC=3)C(C#N)C)=NOC2=C1 HAESZPVRLOMBIW-UHFFFAOYSA-N 0.000 description 1
- AKCRQHGQIJBRMN-UHFFFAOYSA-N 2-chloroaniline Chemical compound NC1=CC=CC=C1Cl AKCRQHGQIJBRMN-UHFFFAOYSA-N 0.000 description 1
- MNNZINNZIQVULG-UHFFFAOYSA-N 2-chloroethylbenzene Chemical compound ClCCC1=CC=CC=C1 MNNZINNZIQVULG-UHFFFAOYSA-N 0.000 description 1
- TYNMSHMBPNRTDN-UHFFFAOYSA-N 3,3,4-trimethyl-1,4-dihydroquinolin-2-one Chemical compound C1=CC=C2NC(=O)C(C)(C)C(C)C2=C1 TYNMSHMBPNRTDN-UHFFFAOYSA-N 0.000 description 1
- OITTVGIRLCPSNN-UHFFFAOYSA-N 3,4-dimethyl-1h-quinolin-2-one Chemical compound C1=CC=C2C(C)=C(C)C(=O)NC2=C1 OITTVGIRLCPSNN-UHFFFAOYSA-N 0.000 description 1
- SEQPVCIAWHVRTD-UHFFFAOYSA-N 3,4-dimethyl-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2NC(=O)C(C)C(C)C2=C1 SEQPVCIAWHVRTD-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- QPHAGNNWDZSKJH-UHFFFAOYSA-N 3-chloro-2h-indazole Chemical compound C1=CC=CC2=C(Cl)NN=C21 QPHAGNNWDZSKJH-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- QTUALOBOYVZREW-UHFFFAOYSA-N 3-ethylpent-2-enoyl chloride Chemical compound CCC(CC)=CC(Cl)=O QTUALOBOYVZREW-UHFFFAOYSA-N 0.000 description 1
- SLDLVGFPFFLYBM-UHFFFAOYSA-N 3-fluoro-2-methyl-aniline Chemical compound CC1=C(N)C=CC=C1F SLDLVGFPFFLYBM-UHFFFAOYSA-N 0.000 description 1
- PAYZSIVVDPEWGA-UHFFFAOYSA-N 3-methyl-n-(2-methylphenyl)but-2-enamide Chemical compound CC(C)=CC(=O)NC1=CC=CC=C1C PAYZSIVVDPEWGA-UHFFFAOYSA-N 0.000 description 1
- HCNSJWYUKDBQNO-UHFFFAOYSA-N 3-piperazin-1-yl-1h-indazole Chemical compound C1CNCCN1C1=NNC2=CC=CC=C12 HCNSJWYUKDBQNO-UHFFFAOYSA-N 0.000 description 1
- NRCINBYEWPFZEH-UHFFFAOYSA-N 4,4-dimethyl-1-azatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-2-one Chemical compound C1CCC2=CC=CC3=C2N1C(=O)CC3(C)C NRCINBYEWPFZEH-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
- 108091005479 5-HT2 receptors Proteins 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- 101710138068 5-hydroxytryptamine receptor 1D Proteins 0.000 description 1
- MLIHAILNQREVLG-UHFFFAOYSA-N 5-methoxy-3-piperazin-1-yl-1,2-benzothiazole Chemical compound C12=CC(OC)=CC=C2SN=C1N1CCNCC1 MLIHAILNQREVLG-UHFFFAOYSA-N 0.000 description 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
- SIRSWYWAAKRISR-UHFFFAOYSA-N 6-(2-chloroacetyl)-1,3,3,4,4-pentamethylquinolin-2-one Chemical compound ClCC(=O)C1=CC=C2N(C)C(=O)C(C)(C)C(C)(C)C2=C1 SIRSWYWAAKRISR-UHFFFAOYSA-N 0.000 description 1
- OVKSWWSYLOUFQC-UHFFFAOYSA-N 6-(2-chloroacetyl)-1,4,4-trimethyl-3h-quinolin-2-one Chemical compound ClCC(=O)C1=CC=C2N(C)C(=O)CC(C)(C)C2=C1 OVKSWWSYLOUFQC-UHFFFAOYSA-N 0.000 description 1
- UZAMEBCUIIQLLB-UHFFFAOYSA-N 6-(2-chloroacetyl)-1,4-dimethyl-3,4-dihydroquinolin-2-one Chemical compound C1=C(C(=O)CCl)C=C2C(C)CC(=O)N(C)C2=C1 UZAMEBCUIIQLLB-UHFFFAOYSA-N 0.000 description 1
- MUINYGKUQVSOQQ-UHFFFAOYSA-N 6-(2-chloroacetyl)-3,3-dimethyl-1,4-dihydroquinolin-2-one Chemical compound ClCC(=O)C1=CC=C2NC(=O)C(C)(C)CC2=C1 MUINYGKUQVSOQQ-UHFFFAOYSA-N 0.000 description 1
- HQJUNOVGRMFCOF-UHFFFAOYSA-N 6-(2-chloroacetyl)-3,4-dimethyl-1h-quinolin-2-one Chemical compound C1=C(C(=O)CCl)C=C2C(C)=C(C)C(=O)NC2=C1 HQJUNOVGRMFCOF-UHFFFAOYSA-N 0.000 description 1
- SWJHLAOHTBELOV-UHFFFAOYSA-N 6-(2-chloroacetyl)-3,4-dimethyl-3,4-dihydro-1h-quinolin-2-one Chemical compound ClCC(=O)C1=CC=C2NC(=O)C(C)C(C)C2=C1 SWJHLAOHTBELOV-UHFFFAOYSA-N 0.000 description 1
- FVYFCWJIPCAEAV-UHFFFAOYSA-N 6-(2-chloroacetyl)-3-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound ClCC(=O)C1=CC=C2NC(=O)C(C)CC2=C1 FVYFCWJIPCAEAV-UHFFFAOYSA-N 0.000 description 1
- TVCWQFOAAIDHFX-UHFFFAOYSA-N 6-(2-chloroacetyl)-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound C1=C(C(=O)CCl)C=C2C(C)(C)CC(=O)NC2=C1 TVCWQFOAAIDHFX-UHFFFAOYSA-N 0.000 description 1
- MEQNDIBPLZUSEM-UHFFFAOYSA-N 6-(2-chloroacetyl)-4-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=C(C(=O)CCl)C=C2C(C)CC(=O)NC2=C1 MEQNDIBPLZUSEM-UHFFFAOYSA-N 0.000 description 1
- KJHOGDDQWIRIRU-UHFFFAOYSA-N 6-(2-chloroacetyl)-8-ethyl-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound N1C(=O)CC(C)(C)C2=C1C(CC)=CC(C(=O)CCl)=C2 KJHOGDDQWIRIRU-UHFFFAOYSA-N 0.000 description 1
- HGKLPKKLXDJQNH-UHFFFAOYSA-N 6-(2-chloroacetyl)-9,9-dimethyl-1-azatricyclo[6.3.1.04,12]dodeca-4(12),5,7-trien-11-one Chemical compound C1CC2=CC(C(=O)CCl)=CC3=C2N1C(=O)CC3(C)C HGKLPKKLXDJQNH-UHFFFAOYSA-N 0.000 description 1
- BKEBRJTXZMXAON-UHFFFAOYSA-N 6-(2-chloroethyl)-1,3,3,4,4-pentamethylquinolin-2-one Chemical compound ClCCC1=CC=C2N(C)C(=O)C(C)(C)C(C)(C)C2=C1 BKEBRJTXZMXAON-UHFFFAOYSA-N 0.000 description 1
- ITHLTIHLNHSXQM-UHFFFAOYSA-N 6-(2-chloroethyl)-1,4,4-trimethyl-3h-quinolin-2-one Chemical compound ClCCC1=CC=C2N(C)C(=O)CC(C)(C)C2=C1 ITHLTIHLNHSXQM-UHFFFAOYSA-N 0.000 description 1
- XCPSSKXJXQEAHP-UHFFFAOYSA-N 6-(2-chloroethyl)-1,4-dimethyl-3,4-dihydroquinolin-2-one Chemical compound C1=C(CCCl)C=C2C(C)CC(=O)N(C)C2=C1 XCPSSKXJXQEAHP-UHFFFAOYSA-N 0.000 description 1
- HBJCHGSYYDFVBJ-UHFFFAOYSA-N 6-(2-chloroethyl)-3,3,4-trimethyl-1,4-dihydroquinolin-2-one Chemical compound ClCCC1=CC=C2NC(=O)C(C)(C)C(C)C2=C1 HBJCHGSYYDFVBJ-UHFFFAOYSA-N 0.000 description 1
- OTMGNGJVFUPUJD-UHFFFAOYSA-N 6-(2-chloroethyl)-3,3-dimethyl-1,4-dihydroquinolin-2-one Chemical compound ClCCC1=CC=C2NC(=O)C(C)(C)CC2=C1 OTMGNGJVFUPUJD-UHFFFAOYSA-N 0.000 description 1
- JKGRYMGZYAHJPN-UHFFFAOYSA-N 6-(2-chloroethyl)-3,4-dimethyl-1h-quinolin-2-one Chemical compound C1=C(CCCl)C=C2C(C)=C(C)C(=O)NC2=C1 JKGRYMGZYAHJPN-UHFFFAOYSA-N 0.000 description 1
- VDPYXBMFRHEOSH-UHFFFAOYSA-N 6-(2-chloroethyl)-3,4-dimethyl-3,4-dihydro-1h-quinolin-2-one Chemical compound ClCCC1=CC=C2NC(=O)C(C)C(C)C2=C1 VDPYXBMFRHEOSH-UHFFFAOYSA-N 0.000 description 1
- PRGLDFWIDRCJMI-UHFFFAOYSA-N 6-(2-chloroethyl)-3-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound ClCCC1=CC=C2NC(=O)C(C)CC2=C1 PRGLDFWIDRCJMI-UHFFFAOYSA-N 0.000 description 1
- UOYNXQYJKMLTGN-UHFFFAOYSA-N 6-(2-chloroethyl)-4-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=C(CCCl)C=C2C(C)CC(=O)NC2=C1 UOYNXQYJKMLTGN-UHFFFAOYSA-N 0.000 description 1
- XVRNTJCHONOSKB-UHFFFAOYSA-N 6-(2-chloroethyl)-8-ethyl-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound N1C(=O)CC(C)(C)C2=C1C(CC)=CC(CCCl)=C2 XVRNTJCHONOSKB-UHFFFAOYSA-N 0.000 description 1
- WPLGBUTVLKDNRT-UHFFFAOYSA-N 6-(2-chloroethyl)-9,9-dimethyl-1-azatricyclo[6.3.1.04,12]dodeca-4(12),5,7-trien-11-one Chemical compound C1CC2=CC(CCCl)=CC3=C2N1C(=O)CC3(C)C WPLGBUTVLKDNRT-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- RRAOJQMZNXISNK-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1-(2,2-dimethylpropyl)-4,4,8-trimethyl-3h-quinolin-2-one Chemical compound CC(C)(C)CN1C(=O)CC(C)(C)C2=C1C(C)=CC(CCN1CCN(CC1)C=1C3=CC=CC=C3SN=1)=C2 RRAOJQMZNXISNK-UHFFFAOYSA-N 0.000 description 1
- UMLQRHJPXZOWGV-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1-(2-methoxyethyl)-3,4-dimethylquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4N(C(C(C)=C(C)C4=C3)=O)CCOC)=NSC2=C1 UMLQRHJPXZOWGV-UHFFFAOYSA-N 0.000 description 1
- FEWKARHQWOJWTE-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1-(2-methoxyethyl)-3-methyl-3,4-dihydroquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(C)C(=O)N(C4=CC=3)CCOC)=NSC2=C1 FEWKARHQWOJWTE-UHFFFAOYSA-N 0.000 description 1
- CTOWHBWOHQSOAN-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-3,3-dimethyl-4h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(C)(C)C(=O)N(C4=CC=3)CC(=O)C(C)(C)C)=NSC2=C1 CTOWHBWOHQSOAN-UHFFFAOYSA-N 0.000 description 1
- WYNMVHZUDKJGOA-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-3-methyl-3,4-dihydroquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(C(N(CC(=O)C(C)(C)C)C4=CC=3)=O)C)=NSC2=C1 WYNMVHZUDKJGOA-UHFFFAOYSA-N 0.000 description 1
- DZMBZLFFEGJRSH-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-4-methyl-3,4-dihydroquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4N(CC(=O)C(C)(C)C)C(=O)CC(C4=C3)C)=NSC2=C1 DZMBZLFFEGJRSH-UHFFFAOYSA-N 0.000 description 1
- KSDXWDWFLMODMI-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1-(cyclobutylmethyl)-4,4,8-trimethyl-3h-quinolin-2-one Chemical compound CC1=CC(CCN2CCN(CC2)C=2C3=CC=CC=C3SN=2)=CC(C(CC2=O)(C)C)=C1N2CC1CCC1 KSDXWDWFLMODMI-UHFFFAOYSA-N 0.000 description 1
- UWZFDHPZIFRJMG-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1-(cyclohexylmethyl)-4,4,8-trimethyl-3h-quinolin-2-one Chemical compound CC1=CC(CCN2CCN(CC2)C=2C3=CC=CC=C3SN=2)=CC(C(CC2=O)(C)C)=C1N2CC1CCCCC1 UWZFDHPZIFRJMG-UHFFFAOYSA-N 0.000 description 1
- PLIYAHWYVSWZFV-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1-(methoxymethyl)-3,3-dimethyl-4h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(C)(C)C(=O)N(C4=CC=3)COC)=NSC2=C1 PLIYAHWYVSWZFV-UHFFFAOYSA-N 0.000 description 1
- KSKDSCPRSYAFIJ-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1-butyl-4,4,8-trimethyl-3h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)CC(=O)N(C4=C(C)C=3)CCCC)=NSC2=C1 KSKDSCPRSYAFIJ-UHFFFAOYSA-N 0.000 description 1
- JFJSBPFGPIANTN-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1-cyclobutyl-4,4,8-trimethyl-3h-quinolin-2-one Chemical compound CC1=CC(CCN2CCN(CC2)C=2C3=CC=CC=C3SN=2)=CC(C(CC2=O)(C)C)=C1N2C1CCC1 JFJSBPFGPIANTN-UHFFFAOYSA-N 0.000 description 1
- NQJZWOXKZHIVLQ-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1-ethyl-3,3-dimethyl-4h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(C)(C)C(=O)N(C4=CC=3)CC)=NSC2=C1 NQJZWOXKZHIVLQ-UHFFFAOYSA-N 0.000 description 1
- FRPBERSOHLPVNE-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1-ethyl-3,4-dimethylquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4N(C(C(C)=C(C)C4=C3)=O)CC)=NSC2=C1 FRPBERSOHLPVNE-UHFFFAOYSA-N 0.000 description 1
- ZJOXXUAOGKWKNS-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-1-ethyl-4-methyl-3,4-dihydroquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C)CC(=O)N(C4=CC=3)CC)=NSC2=C1 ZJOXXUAOGKWKNS-UHFFFAOYSA-N 0.000 description 1
- IKXBUNFNLMWNGH-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-1,4-dihydroquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(C(NC4=CC=3)=O)(C)C)=NSC2=C1 IKXBUNFNLMWNGH-UHFFFAOYSA-N 0.000 description 1
- LKEPVFGOAVOGEX-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-1-(2-methylpropyl)-4h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(C)(C)C(=O)N(C4=CC=3)CC(C)C)=NSC2=C1 LKEPVFGOAVOGEX-UHFFFAOYSA-N 0.000 description 1
- ROWGBSHJSCGSPP-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-3,3-dimethyl-1-phenacyl-4h-quinolin-2-one Chemical compound O=C1C(C)(C)CC2=CC(CCN3CCN(CC3)C=3C4=CC=CC=C4SN=3)=CC=C2N1CC(=O)C1=CC=CC=C1 ROWGBSHJSCGSPP-UHFFFAOYSA-N 0.000 description 1
- DJLPJROWMOTVLU-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1-(2,2,2-trifluoroethyl)quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4N(CC(F)(F)F)C(=O)C(C)=C(C4=C3)C)=NSC2=C1 DJLPJROWMOTVLU-UHFFFAOYSA-N 0.000 description 1
- HTPIFRUAWHSTHN-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1-(2-methylpropyl)quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4N(C(C(C)=C(C)C4=C3)=O)CC(C)C)=NSC2=C1 HTPIFRUAWHSTHN-UHFFFAOYSA-N 0.000 description 1
- DOLDABDRSITEHD-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-3-ethyl-4-methyl-1h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C)=C(C(NC4=CC=3)=O)CC)=NSC2=C1 DOLDABDRSITEHD-UHFFFAOYSA-N 0.000 description 1
- QGOFTOVULIKZJR-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-3-methyl-1-(2-methylpropyl)-3,4-dihydroquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CC(C)C(=O)N(C4=CC=3)CC(C)C)=NSC2=C1 QGOFTOVULIKZJR-UHFFFAOYSA-N 0.000 description 1
- YDHANDXWVICNNE-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-1-(2-methylpropyl)-3h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)CC(=O)N(C4=C(C)C=3)CC(C)C)=NSC2=C1 YDHANDXWVICNNE-UHFFFAOYSA-N 0.000 description 1
- NLETXBXLAJORGC-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-1-pentyl-3h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)CC(=O)N(C4=C(C)C=3)CCCCC)=NSC2=C1 NLETXBXLAJORGC-UHFFFAOYSA-N 0.000 description 1
- PIZHKVZJSUOJHU-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-4-(trifluoromethyl)-1h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(=O)C=C(C4=C3)C(F)(F)F)=NSC2=C1 PIZHKVZJSUOJHU-UHFFFAOYSA-N 0.000 description 1
- YVYNKDSUDUACGH-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-4-ethyl-1h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(=O)C=C(C4=C3)CC)=NSC2=C1 YVYNKDSUDUACGH-UHFFFAOYSA-N 0.000 description 1
- RYNPKWZATSQSIY-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-1-(2-methylpropyl)-3,4-dihydroquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C)CC(=O)N(C4=CC=3)CC(C)C)=NSC2=C1 RYNPKWZATSQSIY-UHFFFAOYSA-N 0.000 description 1
- RWGSICJCYKRHGH-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-1h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(=O)C=C(C4=C3)C)=NSC2=C1 RWGSICJCYKRHGH-UHFFFAOYSA-N 0.000 description 1
- DDDFNRFUQHBPJA-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(=O)CC(C4=C3)C)=NSC2=C1 DDDFNRFUQHBPJA-UHFFFAOYSA-N 0.000 description 1
- FCMMVPGTSQEFNP-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-4-phenyl-1h-quinolin-2-one Chemical compound C12=CC(CCN3CCN(CC3)C=3C4=CC=CC=C4SN=3)=CC=C2NC(=O)C=C1C1=CC=CC=C1 FCMMVPGTSQEFNP-UHFFFAOYSA-N 0.000 description 1
- RLYRZGRGQJMLOK-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-4-propan-2-yl-1h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(=O)C=C(C4=C3)C(C)C)=NSC2=C1 RLYRZGRGQJMLOK-UHFFFAOYSA-N 0.000 description 1
- SHEQTHKALAHXSJ-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-4-propyl-1h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(=O)C=C(C4=C3)CCC)=NSC2=C1 SHEQTHKALAHXSJ-UHFFFAOYSA-N 0.000 description 1
- HCLNXEMEOXPYGA-UHFFFAOYSA-N 6-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-9,9-dimethyl-1-azatricyclo[6.3.1.04,12]dodeca-4(12),5,7-trien-11-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4CCN5C(=O)CC(C(C=3)=C54)(C)C)=NSC2=C1 HCLNXEMEOXPYGA-UHFFFAOYSA-N 0.000 description 1
- PIJCEMMBRUFGIJ-UHFFFAOYSA-N 6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-1,4,4-trimethyl-3h-quinolin-2-one;hydrochloride Chemical compound Cl.C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)CC(=O)N(C4=CC=3)C)=NOC2=C1 PIJCEMMBRUFGIJ-UHFFFAOYSA-N 0.000 description 1
- ZDZJSKNWTFOYCG-UHFFFAOYSA-N 6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-1,4-dimethyl-3,4-dihydroquinolin-2-one;hydrochloride Chemical compound Cl.C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4N(C)C(=O)CC(C4=C3)C)=NOC2=C1 ZDZJSKNWTFOYCG-UHFFFAOYSA-N 0.000 description 1
- AJBQKRALFHNZIL-UHFFFAOYSA-N 6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-1-(2-methoxyethyl)-3,4-dimethylquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4N(C(C(C)=C(C)C4=C3)=O)CCOC)=NOC2=C1 AJBQKRALFHNZIL-UHFFFAOYSA-N 0.000 description 1
- GSLXBQGIZJPUPL-UHFFFAOYSA-N 6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-1-(2-methoxyethyl)-4-methyl-3,4-dihydroquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C)CC(=O)N(C4=CC=3)CCOC)=NOC2=C1 GSLXBQGIZJPUPL-UHFFFAOYSA-N 0.000 description 1
- BYSNEHIHLQDIJQ-UHFFFAOYSA-N 6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-1-(3,3-dimethyl-2-oxobutyl)-4-methyl-3,4-dihydroquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4N(CC(=O)C(C)(C)C)C(=O)CC(C4=C3)C)=NOC2=C1 BYSNEHIHLQDIJQ-UHFFFAOYSA-N 0.000 description 1
- SVSWESDZEDFJIU-UHFFFAOYSA-N 6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-1-ethyl-3,4-dimethylquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4N(C(C(C)=C(C)C4=C3)=O)CC)=NOC2=C1 SVSWESDZEDFJIU-UHFFFAOYSA-N 0.000 description 1
- RVZJMTPMQDKNIN-UHFFFAOYSA-N 6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-1-ethyl-4-methyl-3,4-dihydroquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C)CC(=O)N(C4=CC=3)CC)=NOC2=C1 RVZJMTPMQDKNIN-UHFFFAOYSA-N 0.000 description 1
- RPJZIMZTDMDUOB-UHFFFAOYSA-N 6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1-(2,2,2-trifluoroethyl)quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4N(CC(F)(F)F)C(=O)C(C)=C(C4=C3)C)=NOC2=C1 RPJZIMZTDMDUOB-UHFFFAOYSA-N 0.000 description 1
- WDCMNOISJHHORH-UHFFFAOYSA-N 6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1-phenacylquinolin-2-one Chemical compound C12=CC=C(CCN3CCN(CC3)C=3C4=CC=CC=C4ON=3)C=C2C(C)=C(C)C(=O)N1CC(=O)C1=CC=CC=C1 WDCMNOISJHHORH-UHFFFAOYSA-N 0.000 description 1
- KPDQSVFYCRTOLA-UHFFFAOYSA-N 6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1h-quinolin-2-one;hydrochloride Chemical compound Cl.C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(=O)C(C)=C(C4=C3)C)=NOC2=C1 KPDQSVFYCRTOLA-UHFFFAOYSA-N 0.000 description 1
- QKVDPRVDWXJHDV-UHFFFAOYSA-N 6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-4,4,8-trimethyl-1,3-dihydroquinolin-2-one Chemical compound N1C(=O)CC(C)(C)C2=C1C(C)=CC(CCN1CCN(CC1)C=1C3=CC=CC=C3ON=1)=C2 QKVDPRVDWXJHDV-UHFFFAOYSA-N 0.000 description 1
- GSIYBQPEFHHZSA-UHFFFAOYSA-N 6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-4-methyl-1-(2-methylpropyl)-3,4-dihydroquinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C)CC(=O)N(C4=CC=3)CC(C)C)=NOC2=C1 GSIYBQPEFHHZSA-UHFFFAOYSA-N 0.000 description 1
- WRELFPNVMRCGBT-UHFFFAOYSA-N 6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-8-ethyl-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound N1C(=O)CC(C)(C)C2=C1C(CC)=CC(CCN1CCN(CC1)C=1C3=CC=CC=C3ON=1)=C2 WRELFPNVMRCGBT-UHFFFAOYSA-N 0.000 description 1
- VQKFYCZDULPYSF-UHFFFAOYSA-N 6-[2-[4-(1h-indazol-3-yl)piperazin-1-yl]ethyl]-1,4,4-trimethyl-3h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)CC(=O)N(C4=CC=3)C)=NNC2=C1 VQKFYCZDULPYSF-UHFFFAOYSA-N 0.000 description 1
- RMEJSMRLRVYKLQ-UHFFFAOYSA-N 6-[2-[4-(1h-indazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1h-quinolin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(=O)C(C)=C(C4=C3)C)=NNC2=C1 RMEJSMRLRVYKLQ-UHFFFAOYSA-N 0.000 description 1
- UVMWPEHDAUVCRU-UHFFFAOYSA-N 6-[2-[4-(6-fluoro-1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-1h-quinolin-2-one Chemical compound FC1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(=O)C(C)=C(C4=C3)C)=NSC2=C1 UVMWPEHDAUVCRU-UHFFFAOYSA-N 0.000 description 1
- DVPGENRYPBKVHV-UHFFFAOYSA-N 6-[2-[4-(6-fluoro-1,2-benzothiazol-3-yl)piperidin-1-yl]ethyl]-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC3=CC=C4NC(=O)CC(C4=C3)(C)C)=NSC2=C1 DVPGENRYPBKVHV-UHFFFAOYSA-N 0.000 description 1
- AZXSZYDCMHNUML-UHFFFAOYSA-N 6-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC3=CC=C4NC(=O)CC(C4=C3)(C)C)=NOC2=C1 AZXSZYDCMHNUML-UHFFFAOYSA-N 0.000 description 1
- NJKPASFMLULYAQ-UHFFFAOYSA-N 6-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-7-fluoro-1,4,4-trimethyl-3h-quinolin-2-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC=C2C(N3CCN(CC3)CCCC=3C=C4C(C)(C)CC(=O)N(C4=CC=3F)C)=NSC2=C1 NJKPASFMLULYAQ-UHFFFAOYSA-N 0.000 description 1
- CPBRJIFWHROYKA-UHFFFAOYSA-N 6-fluoro-3-piperazin-1-yl-1,2-benzoxazole Chemical compound N=1OC2=CC(F)=CC=C2C=1N1CCNCC1 CPBRJIFWHROYKA-UHFFFAOYSA-N 0.000 description 1
- VNEAVFDXEDUSBU-UHFFFAOYSA-N 6-fluoro-3-piperazin-1-yl-1,2-benzoxazole;hydrochloride Chemical compound Cl.N=1OC2=CC(F)=CC=C2C=1N1CCNCC1 VNEAVFDXEDUSBU-UHFFFAOYSA-N 0.000 description 1
- NPIPDFQZQCZATJ-UHFFFAOYSA-N 6-fluoro-3-piperidin-4-yl-1,2-benzothiazole Chemical compound N=1SC2=CC(F)=CC=C2C=1C1CCNCC1 NPIPDFQZQCZATJ-UHFFFAOYSA-N 0.000 description 1
- MRMGJMGHPJZSAE-UHFFFAOYSA-N 6-fluoro-3-piperidin-4-yl-1,2-benzoxazole Chemical compound N=1OC2=CC(F)=CC=C2C=1C1CCNCC1 MRMGJMGHPJZSAE-UHFFFAOYSA-N 0.000 description 1
- BZRNYXBDHSNFNN-UHFFFAOYSA-N 6-methyl-3-piperazin-1-yl-1,2-benzoxazole Chemical compound N=1OC2=CC(C)=CC=C2C=1N1CCNCC1 BZRNYXBDHSNFNN-UHFFFAOYSA-N 0.000 description 1
- CAEUWRCNRDSPCN-UHFFFAOYSA-N 7-(2-chloroacetyl)-1-azatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-2-one Chemical compound O=C1CCC2=CC(C(=O)CCl)=CC3=C2N1CCC3 CAEUWRCNRDSPCN-UHFFFAOYSA-N 0.000 description 1
- KDJRWYUGQARJLL-UHFFFAOYSA-N 7-(2-chloroacetyl)-4,4-dimethyl-1-azatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-2-one Chemical compound C1CCC2=CC(C(=O)CCl)=CC3=C2N1C(=O)CC3(C)C KDJRWYUGQARJLL-UHFFFAOYSA-N 0.000 description 1
- GRRATAYGZQOGII-UHFFFAOYSA-N 7-(2-chloroethyl)-1-azatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-2-one Chemical compound O=C1CCC2=CC(CCCl)=CC3=C2N1CCC3 GRRATAYGZQOGII-UHFFFAOYSA-N 0.000 description 1
- WPUJWUALERDEKM-UHFFFAOYSA-N 7-(2-chloroethyl)-4,4-dimethyl-1-azatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-2-one Chemical compound C1CCC2=CC(CCCl)=CC3=C2N1C(=O)CC3(C)C WPUJWUALERDEKM-UHFFFAOYSA-N 0.000 description 1
- XOCSIBQQEXKLPV-UHFFFAOYSA-N 7-chloro-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound ClC1=CC=C2C(C)(C)CC(=O)NC2=C1 XOCSIBQQEXKLPV-UHFFFAOYSA-N 0.000 description 1
- VLZIEGHDLFEQOR-UHFFFAOYSA-N 7-chloro-6-(2-chloroacetyl)-4,4,8-trimethyl-1,3-dihydroquinolin-2-one Chemical compound N1C(=O)CC(C)(C)C2=C1C(C)=C(Cl)C(C(=O)CCl)=C2 VLZIEGHDLFEQOR-UHFFFAOYSA-N 0.000 description 1
- ILMDLHZQZGLJQI-UHFFFAOYSA-N 7-chloro-6-(2-chloroethyl)-4,4,8-trimethyl-1,3-dihydroquinolin-2-one Chemical compound N1C(=O)CC(C)(C)C2=C1C(C)=C(Cl)C(CCCl)=C2 ILMDLHZQZGLJQI-UHFFFAOYSA-N 0.000 description 1
- KUASBUPLYHRBNQ-UHFFFAOYSA-N 7-fluoro-3-piperazin-1-yl-1,2-benzothiazole Chemical compound N=1SC=2C(F)=CC=CC=2C=1N1CCNCC1 KUASBUPLYHRBNQ-UHFFFAOYSA-N 0.000 description 1
- UOFJBXPNELJVCM-UHFFFAOYSA-N 7-fluoro-3-piperazin-1-yl-1,2-benzothiazole;hydrochloride Chemical compound Cl.N=1SC=2C(F)=CC=CC=2C=1N1CCNCC1 UOFJBXPNELJVCM-UHFFFAOYSA-N 0.000 description 1
- KRNLKGNECZGVPJ-UHFFFAOYSA-N 7-fluoro-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound FC1=CC=C2C(C)(C)CC(=O)NC2=C1 KRNLKGNECZGVPJ-UHFFFAOYSA-N 0.000 description 1
- BGIMOMCQXOGPPC-UHFFFAOYSA-N 7-methoxy-3-piperazin-1-yl-1,2-benzothiazole Chemical compound N=1SC=2C(OC)=CC=CC=2C=1N1CCNCC1 BGIMOMCQXOGPPC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- ABWSPZGEQFRFBL-UHFFFAOYSA-N 8-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-3,5-dihydro-1h-furo[3,4-c]quinolin-4-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(C=5COCC=5C4=C3)=O)=NSC2=C1 ABWSPZGEQFRFBL-UHFFFAOYSA-N 0.000 description 1
- WJHJOHZAGGCQTO-UHFFFAOYSA-N 8-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-5-methyl-2,3-dihydro-1h-cyclopenta[c]quinolin-4-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4N(C(C=5CCCC=5C4=C3)=O)C)=NSC2=C1 WJHJOHZAGGCQTO-UHFFFAOYSA-N 0.000 description 1
- WVGTYRZTDGQFDN-UHFFFAOYSA-N 8-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-3,5-dihydro-1h-furo[3,4-c]quinolin-4-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4NC(C=5COCC=5C4=C3)=O)=NOC2=C1 WVGTYRZTDGQFDN-UHFFFAOYSA-N 0.000 description 1
- UFABHJCTSXUBFZ-UHFFFAOYSA-N 8-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propoxy]-1,2,3,5-tetrahydrocyclopenta[c]quinolin-4-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCCOC3=CC=C4NC(C=5CCCC=5C4=C3)=O)=NSC2=C1 UFABHJCTSXUBFZ-UHFFFAOYSA-N 0.000 description 1
- MXOZITUXSCGUCE-UHFFFAOYSA-N 8-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-2-methyl-3,5-dihydro-1h-pyrrolo[3,4-c]quinolin-4-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCCC3=CC=C4NC(=O)C5=C(C4=C3)CN(C5)C)=NSC2=C1 MXOZITUXSCGUCE-UHFFFAOYSA-N 0.000 description 1
- MGNGVGVCXXTXHD-UHFFFAOYSA-N 8-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-3,5-dihydro-1h-furo[3,4-c]quinolin-4-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCCC3=CC=C4NC(C=5COCC=5C4=C3)=O)=NSC2=C1 MGNGVGVCXXTXHD-UHFFFAOYSA-N 0.000 description 1
- RIZACARHTIOLTP-UHFFFAOYSA-N 8-chloro-6-(2-chloroacetyl)-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound C1=C(C(=O)CCl)C=C2C(C)(C)CC(=O)NC2=C1Cl RIZACARHTIOLTP-UHFFFAOYSA-N 0.000 description 1
- PANCKPIWUCYIBK-UHFFFAOYSA-N 8-chloro-6-(2-chloroethyl)-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound C1=C(CCCl)C=C2C(C)(C)CC(=O)NC2=C1Cl PANCKPIWUCYIBK-UHFFFAOYSA-N 0.000 description 1
- ZMVOOZIBEWSPKE-UHFFFAOYSA-N 9,9-dimethyl-1-azatricyclo[6.3.1.04,12]dodeca-4(12),5,7-trien-11-one Chemical compound C1CC2=CC=CC3=C2N1C(=O)CC3(C)C ZMVOOZIBEWSPKE-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 229910000906 Bronze Inorganic materials 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KGGXSRYXRGCXCA-UHFFFAOYSA-N Cl.C1=C(F)C=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)CC(=O)N(C4=C(C)C=3)C(C)C)=NSC2=C1 Chemical compound Cl.C1=C(F)C=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)CC(=O)N(C4=C(C)C=3)C(C)C)=NSC2=C1 KGGXSRYXRGCXCA-UHFFFAOYSA-N 0.000 description 1
- PJXWONNLWIOVNR-UHFFFAOYSA-N Cl.C1=C(F)C=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)CC(=O)N(C4=C(C)C=3)C)=NSC2=C1 Chemical compound Cl.C1=C(F)C=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)CC(=O)N(C4=C(C)C=3)C)=NSC2=C1 PJXWONNLWIOVNR-UHFFFAOYSA-N 0.000 description 1
- UFCYMXZIGFPHIV-UHFFFAOYSA-N Cl.C1=C(F)C=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)CC(=O)N(C4=C(C)C=3)CC)=NSC2=C1 Chemical compound Cl.C1=C(F)C=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)CC(=O)N(C4=C(C)C=3)CC)=NSC2=C1 UFCYMXZIGFPHIV-UHFFFAOYSA-N 0.000 description 1
- YGBLQZCSWNWRLO-UHFFFAOYSA-N Cl.C1=C(F)C=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)CC(=O)N(C4=C(C)C=3)CCC)=NSC2=C1 Chemical compound Cl.C1=C(F)C=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)CC(=O)N(C4=C(C)C=3)CCC)=NSC2=C1 YGBLQZCSWNWRLO-UHFFFAOYSA-N 0.000 description 1
- YDGMVVIALDTQTN-UHFFFAOYSA-N Cl.C1=C(F)C=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)CC(=O)N(C4=C(C)C=3)CCOCC)=NSC2=C1 Chemical compound Cl.C1=C(F)C=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)CC(=O)N(C4=C(C)C=3)CCOCC)=NSC2=C1 YDGMVVIALDTQTN-UHFFFAOYSA-N 0.000 description 1
- XBTUKBWAXYNGIM-UHFFFAOYSA-N Cl.C1=C(F)C=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)CC(=O)N(C4=C(C)C=3)COC)=NSC2=C1 Chemical compound Cl.C1=C(F)C=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)CC(=O)N(C4=C(C)C=3)COC)=NSC2=C1 XBTUKBWAXYNGIM-UHFFFAOYSA-N 0.000 description 1
- XTLCYJKKBDEPQO-UHFFFAOYSA-N Cl.C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)C(C)(C)C(=O)N(C4=CC=3)C)=NSC2=C1 Chemical compound Cl.C1=CC=C2C(N3CCN(CC3)CCC=3C=C4C(C)(C)C(C)(C)C(=O)N(C4=CC=3)C)=NSC2=C1 XTLCYJKKBDEPQO-UHFFFAOYSA-N 0.000 description 1
- JKDPTAPJYMRWFN-UHFFFAOYSA-N ClCC(=O)C1=CC=C2NC(=O)C(C)(C)C(C)C2=C1 Chemical compound ClCC(=O)C1=CC=C2NC(=O)C(C)(C)C(C)C2=C1 JKDPTAPJYMRWFN-UHFFFAOYSA-N 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102100020756 D(2) dopamine receptor Human genes 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 101150049660 DRD2 gene Proteins 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101000931901 Homo sapiens D(2) dopamine receptor Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- KRDOFMHJLWKXIU-UHFFFAOYSA-N ID11614 Chemical compound C1CNCCN1C1=NSC2=CC=CC=C12 KRDOFMHJLWKXIU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- FAPDDOBMIUGHIN-UHFFFAOYSA-K antimony trichloride Chemical compound Cl[Sb](Cl)Cl FAPDDOBMIUGHIN-UHFFFAOYSA-K 0.000 description 1
- VMPVEPPRYRXYNP-UHFFFAOYSA-I antimony(5+);pentachloride Chemical compound Cl[Sb](Cl)(Cl)(Cl)Cl VMPVEPPRYRXYNP-UHFFFAOYSA-I 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- DAMJCWMGELCIMI-UHFFFAOYSA-N benzyl n-(2-oxopyrrolidin-3-yl)carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC1CCNC1=O DAMJCWMGELCIMI-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- PVYPHUYXKVVURH-UHFFFAOYSA-N boron;2-methylpropan-2-amine Chemical compound [B].CC(C)(C)N PVYPHUYXKVVURH-UHFFFAOYSA-N 0.000 description 1
- RJTANRZEWTUVMA-UHFFFAOYSA-N boron;n-methylmethanamine Chemical compound [B].CNC RJTANRZEWTUVMA-UHFFFAOYSA-N 0.000 description 1
- 239000010974 bronze Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960004362 clorazepate Drugs 0.000 description 1
- XDDJGVMJFWAHJX-UHFFFAOYSA-M clorazepic acid anion Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)[O-])N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- KUNSUQLRTQLHQQ-UHFFFAOYSA-N copper tin Chemical compound [Cu].[Sn] KUNSUQLRTQLHQQ-UHFFFAOYSA-N 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960001393 dosulepin Drugs 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BTKSUULMJNNXHG-UHFFFAOYSA-N ethyl 2-(methylamino)acetate Chemical compound CCOC(=O)CNC BTKSUULMJNNXHG-UHFFFAOYSA-N 0.000 description 1
- NIDZUMSLERGAON-UHFFFAOYSA-N ethyl 2-(methylamino)acetate;hydron;chloride Chemical compound Cl.CCOC(=O)CNC NIDZUMSLERGAON-UHFFFAOYSA-N 0.000 description 1
- RARTYCZJPFJPBF-UHFFFAOYSA-N ethyl 2-[6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-2-oxoquinolin-1-yl]acetate Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4N(C(C(C)=C(C)C4=C3)=O)CC(=O)OCC)=NOC2=C1 RARTYCZJPFJPBF-UHFFFAOYSA-N 0.000 description 1
- ZANNOFHADGWOLI-UHFFFAOYSA-N ethyl 2-hydroxyacetate Chemical compound CCOC(=O)CO ZANNOFHADGWOLI-UHFFFAOYSA-N 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229960000647 gepirone Drugs 0.000 description 1
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229960002158 halazepam Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 150000002473 indoazoles Chemical class 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 229960002844 iprindole Drugs 0.000 description 1
- PLIGPBGDXASWPX-UHFFFAOYSA-N iprindole Chemical compound C1CCCCCC2=C1N(CCCN(C)C)C1=CC=CC=C12 PLIGPBGDXASWPX-UHFFFAOYSA-N 0.000 description 1
- 229950003599 ipsapirone Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002672 isocarboxazid Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001793 isothiazol-3-yl group Chemical group [H]C1=C([H])C(*)=NS1 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 229960005417 ketanserin Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 229960002813 lofepramine Drugs 0.000 description 1
- SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940087646 methanolamine Drugs 0.000 description 1
- KUGCFHMVZBQFQM-UHFFFAOYSA-N methyl 2-[6-[2-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]ethyl]-3,4-dimethyl-2-oxoquinolin-1-yl]propanoate Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=C4N(C(C(C)=C(C)C4=C3)=O)C(C)C(=O)OC)=NOC2=C1 KUGCFHMVZBQFQM-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- BKKLOPGJHAHWFY-UHFFFAOYSA-N n-(2-chlorophenyl)-3-methylbut-2-enamide Chemical compound CC(C)=CC(=O)NC1=CC=CC=C1Cl BKKLOPGJHAHWFY-UHFFFAOYSA-N 0.000 description 1
- WVPMPVDSVJDKDF-UHFFFAOYSA-N n-(2-ethylphenyl)-3-methylbut-2-enamide Chemical compound CCC1=CC=CC=C1NC(=O)C=C(C)C WVPMPVDSVJDKDF-UHFFFAOYSA-N 0.000 description 1
- VQWFULFTZRVOJJ-UHFFFAOYSA-N n-(3-chloro-2-methylphenyl)-3-methylbut-2-enamide Chemical compound CC(C)=CC(=O)NC1=CC=CC(Cl)=C1C VQWFULFTZRVOJJ-UHFFFAOYSA-N 0.000 description 1
- CEEJZQZEYKKAIG-UHFFFAOYSA-N n-(3-fluoro-2-methylphenyl)-3-methylbut-2-enamide Chemical compound CC(C)=CC(=O)NC1=CC=CC(F)=C1C CEEJZQZEYKKAIG-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 229940078552 o-xylene Drugs 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 229940053544 other antidepressants in atc Drugs 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical class C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- HDMGAZBPFLDBCX-UHFFFAOYSA-M potassium;sulfooxy sulfate Chemical compound [K+].OS(=O)(=O)OOS([O-])(=O)=O HDMGAZBPFLDBCX-UHFFFAOYSA-M 0.000 description 1
- 229960004856 prazepam Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229960001922 sodium perborate Drugs 0.000 description 1
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 1
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- IXZDIALLLMRYOU-UHFFFAOYSA-N tert-butyl hypochlorite Chemical compound CC(C)(C)OCl IXZDIALLLMRYOU-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- PHTUQLWOUWZIMZ-GZTJUZNOSA-N trans-dothiepin Chemical compound C1SC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 PHTUQLWOUWZIMZ-GZTJUZNOSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical group [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960001255 viloxazine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41147502P | 2002-09-17 | 2002-09-17 | |
US41635502P | 2002-10-04 | 2002-10-04 | |
PCT/IB2003/003902 WO2004026864A1 (fr) | 2002-09-17 | 2003-09-05 | Piperazines heterocycliques substituees pour le traitement de la schizophrenie |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20050248A2 true HRP20050248A2 (en) | 2005-10-31 |
Family
ID=32033549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20050248A HRP20050248A2 (en) | 2002-09-17 | 2005-03-16 | Heterocyclic substituted piperazines for the treatment of schizophrenia |
Country Status (25)
Country | Link |
---|---|
US (1) | US20040138230A1 (fr) |
EP (1) | EP1546143A1 (fr) |
JP (1) | JP2006503106A (fr) |
KR (1) | KR20050057404A (fr) |
AP (1) | AP2005003250A0 (fr) |
AR (1) | AR041260A1 (fr) |
AU (1) | AU2003263413A1 (fr) |
BR (1) | BR0314393A (fr) |
CA (1) | CA2499326A1 (fr) |
CO (1) | CO5550472A2 (fr) |
EA (1) | EA200500342A1 (fr) |
EC (1) | ECSP055676A (fr) |
HR (1) | HRP20050248A2 (fr) |
IS (1) | IS7710A (fr) |
MA (1) | MA27438A1 (fr) |
MX (1) | MXPA05002007A (fr) |
NO (1) | NO20051826L (fr) |
OA (1) | OA12923A (fr) |
PA (1) | PA8582601A1 (fr) |
PE (1) | PE20050132A1 (fr) |
PL (1) | PL375981A1 (fr) |
RS (1) | RS20050195A (fr) |
TW (1) | TW200409771A (fr) |
UY (1) | UY27976A1 (fr) |
WO (1) | WO2004026864A1 (fr) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2505397A1 (fr) * | 2002-11-08 | 2004-05-21 | Warner-Lambert Company Llc | Derives de piperazine phenylalkyles et pyridylalkyles |
JP2007513197A (ja) * | 2003-12-08 | 2007-05-24 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 統合失調症の治療のための複素環式置換インダン誘導体および関連化合物 |
MXPA06007654A (es) * | 2003-12-31 | 2006-09-04 | Warner Lambert Co | Derivados de piperidina n-sustituidos. |
US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
US20050256118A1 (en) * | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
WO2006090273A2 (fr) * | 2005-02-22 | 2006-08-31 | Warner-Lambert Company Llc | [1,8]naphthyridin-2-ones et composes relatifs a liants ceto ou hydroxyl destines au traitement de la schizophrenie |
TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
JP4315393B2 (ja) * | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
AR055203A1 (es) | 2005-08-31 | 2007-08-08 | Otsuka Pharma Co Ltd | Derivados de benzotiofeno con propiedades antipsicoticas |
WO2008015516A1 (fr) * | 2006-07-28 | 2008-02-07 | Pfizer Products Inc. | Hétérocycles tricycliques à cycles fusionnés dans le traitement de la schizophrénie |
AR063302A1 (es) * | 2006-10-13 | 2009-01-21 | Otsuka Pharma Co Ltd | Derivados de 4-benzo[b]tiofen-4-il-piperazin-1-il con accion antagonista del receptor 5-ht2a de serotonina y receptor de adrenalina alfa1 y agonista parcial del receptor d2, una composicion farmaceutica que lo comprende y un proceso para producirla. |
JP4540700B2 (ja) * | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
JP4785881B2 (ja) * | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
RU2497819C2 (ru) * | 2007-05-21 | 2013-11-10 | Ривайва Фармасьютикалс, Инк. | Композиции, синтез и способы применения атипичных нейролептиков на основе хинолина |
AU2009244538A1 (en) | 2008-05-08 | 2009-11-12 | Allergan, Inc. | Therapeutically useful substituted 1, 7-diphenyl-l, 2, 3, 5, 6, 7-hexahydropyrido [ 3, 2, 1-I J ] quinoline compounds |
US20090281322A1 (en) * | 2008-05-08 | 2009-11-12 | Allergan, Inc. | THERAPEUTICALLY USEFUL SUBSTITUTED 1,7-DIPHENYL-1,2,3,5,6,7-HEXAHYDROPYRIDO[3,2,1-Ij]QUINOLINE COMPOUNDS |
US8653069B2 (en) * | 2008-07-28 | 2014-02-18 | Jiangsu Hengyi Pharmaceutical Co., Ltd. | Aralkyl substituted piperidine or piperazine derivatives and their use for treating schizophrenia |
CA2735400A1 (fr) | 2008-09-22 | 2010-03-25 | F. Hoffmann-La Roche Ag | Modulateurs des recepteurs d3 et 5-ht2a derives de piperazine |
BRPI0918985A2 (pt) * | 2008-09-23 | 2015-12-01 | Hoffmann La Roche | derivados de benzo[d]isoxazol-3-il-piperazina úteis como moduladores dos receptores d3 de dopamina |
HRP20171415T4 (hr) * | 2009-06-25 | 2023-03-03 | Alkermes Pharma Ireland Limited | Heterociklični spojevi za liječenje neuroloških i psiholoških poremećaja |
AU2014265021B2 (en) * | 2009-06-25 | 2016-07-21 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds |
WO2010151711A1 (fr) | 2009-06-25 | 2010-12-29 | Alkermes, Inc. | Promédicaments de composés nh acides |
TWI503323B (zh) * | 2010-03-29 | 2015-10-11 | Oncotherapy Science Inc | 三環化合物以及含此化合物之pbk抑制劑 |
US8877778B2 (en) | 2010-12-15 | 2014-11-04 | Hoffmann-La Roche Inc. | Benzofurane compounds |
US9034867B2 (en) | 2011-03-18 | 2015-05-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising sorbitan esters |
US8921397B2 (en) | 2011-05-04 | 2014-12-30 | Hoffmann-La Roche Inc. | Benzofurane-piperidine compounds |
EP2736894B1 (fr) | 2011-07-28 | 2016-08-31 | Otsuka Pharmaceutical Co., Ltd. | Rocédé pour la production de composés de benzo[b]thiophène |
JO3227B1 (ar) * | 2011-09-08 | 2018-03-08 | Otsuka Pharma Co Ltd | مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان |
NZ722096A (en) | 2011-12-15 | 2016-11-25 | Alkermes Pharma Ireland Ltd | Prodrugs of secondary amine compounds |
JP6471089B2 (ja) | 2012-03-19 | 2019-02-13 | アルカームス ファーマ アイルランド リミテッド | 脂肪酸エステルを含む医薬組成物 |
CA2867137C (fr) | 2012-03-19 | 2020-12-08 | Alkermes Pharma Ireland Limited | Compositions pharmaceutiques renfermant des promedicaments d'aripiprazole et d'alcool benzylique |
JP6219918B2 (ja) | 2012-03-19 | 2017-10-25 | アルカームス ファーマ アイルランド リミテッド | グリセロールエステルを含む医薬組成物 |
ES2792149T3 (es) | 2012-09-19 | 2020-11-10 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada |
MX2016012041A (es) | 2014-03-20 | 2017-01-19 | Alkermes Pharma Ireland Ltd | Formulaciones de aripiprazol que tienen mayores velocidades de inyeccion. |
JP5714152B2 (ja) * | 2014-03-26 | 2015-05-07 | 江蘇恒誼薬業有限公司 | アラルキルピペリジン(又はピペラジン)誘導体及びその統合失調症治療のための使用 |
CN106608875A (zh) | 2015-10-26 | 2017-05-03 | 江苏恩华药业股份有限公司 | 一种稠和杂环类衍生物合成及其应用 |
CN106749219A (zh) * | 2015-11-20 | 2017-05-31 | 江苏恩华药业股份有限公司 | 一种内酰胺类衍生物及其应用 |
JP7384812B2 (ja) | 2018-03-05 | 2023-11-21 | アルカームス ファーマ アイルランド リミテッド | アリピプラゾール投与戦略 |
WO2020230802A1 (fr) * | 2019-05-14 | 2020-11-19 | 杏林製薬株式会社 | Procédé de production de dérivés de 4-oxopyrrolidine-3-carboxamide |
CN114728956B (zh) * | 2019-11-18 | 2024-01-12 | 上海枢境生物科技有限公司 | 稠和杂环类衍生物及其应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3706427A1 (de) * | 1987-02-27 | 1988-09-08 | Boehringer Mannheim Gmbh | Neue substituierte 3h-indole, zwischenprodukte, verfahren zu ihrer herstellung sowie arzneimittel |
GB8723763D0 (en) * | 1987-10-09 | 1987-11-11 | Hydro Tech Ltd | Liquid flow control device |
US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
ES2076253T3 (es) * | 1989-05-19 | 1995-11-01 | Hoechst Roussel Pharma | N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos. |
US5364866A (en) * | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
US5776963A (en) * | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
JP2768981B2 (ja) * | 1989-06-22 | 1998-06-25 | シャープ株式会社 | 光メモリ素子 |
US5350747A (en) * | 1989-07-07 | 1994-09-27 | Pfizer Inc | Heteroaryl piperazine antipsychotic agents |
WO1991000863A1 (fr) * | 1989-07-07 | 1991-01-24 | Pfizer Inc. | Agents antipsychotiques a base de piperazine d'heteroaryle |
US5147881A (en) * | 1990-11-14 | 1992-09-15 | Pfizer Inc | 4-(1,2-benzisoxazolyl)piperidine antipsychotic agents |
US5143923B1 (en) * | 1991-04-29 | 1993-11-02 | Hoechst-Roussel Pharmaceuticals Incorporated | Benzoisothiazole-and benzisoxazole-3-carboxamides |
MX9201991A (es) * | 1991-05-02 | 1992-11-01 | Jonh Wyeth & Brother Limited | Derivados de piperazina y procedimiento para su preparacion. |
IT1251144B (it) * | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
TW300219B (fr) * | 1991-09-14 | 1997-03-11 | Hoechst Ag | |
US5206366A (en) * | 1992-08-26 | 1993-04-27 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds |
UA57734C2 (uk) * | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
IL125951A (en) * | 1997-09-05 | 2003-09-17 | Pfizer Prod Inc | A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal |
DE19746612A1 (de) * | 1997-10-22 | 1999-04-29 | Basf Ag | 2-Substituierte 1,2-Benzisothiazol-Derivate, ihre Herstellung und Verwendung |
IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
US6387904B2 (en) * | 1998-05-18 | 2002-05-14 | Pfizer Inc | Method of treating glaucoma and ischemic retinopathy |
ME00370B (me) * | 1999-06-23 | 2011-05-10 | Sanofi Aventis Deutschland | SUPSTITUISANI BENZIMIDAZOLl |
-
2003
- 2003-09-05 WO PCT/IB2003/003902 patent/WO2004026864A1/fr not_active Application Discontinuation
- 2003-09-05 BR BR0314393-7A patent/BR0314393A/pt not_active IP Right Cessation
- 2003-09-05 KR KR1020057004592A patent/KR20050057404A/ko active IP Right Grant
- 2003-09-05 AU AU2003263413A patent/AU2003263413A1/en not_active Abandoned
- 2003-09-05 EA EA200500342A patent/EA200500342A1/ru unknown
- 2003-09-05 RS YUP-2005/0195A patent/RS20050195A/sr unknown
- 2003-09-05 PL PL03375981A patent/PL375981A1/xx not_active Application Discontinuation
- 2003-09-05 CA CA002499326A patent/CA2499326A1/fr not_active Abandoned
- 2003-09-05 EP EP03797433A patent/EP1546143A1/fr not_active Withdrawn
- 2003-09-05 MX MXPA05002007A patent/MXPA05002007A/es unknown
- 2003-09-05 AP AP2005003250A patent/AP2005003250A0/xx unknown
- 2003-09-05 JP JP2004568902A patent/JP2006503106A/ja active Pending
- 2003-09-05 OA OA1200500072A patent/OA12923A/en unknown
- 2003-09-12 PE PE2003000930A patent/PE20050132A1/es not_active Application Discontinuation
- 2003-09-12 US US10/660,908 patent/US20040138230A1/en not_active Abandoned
- 2003-09-15 AR ARP030103336A patent/AR041260A1/es unknown
- 2003-09-15 PA PA20038582601A patent/PA8582601A1/es unknown
- 2003-09-15 UY UY27976A patent/UY27976A1/es not_active Application Discontinuation
- 2003-09-16 TW TW092125508A patent/TW200409771A/zh unknown
-
2005
- 2005-02-24 IS IS7710A patent/IS7710A/is unknown
- 2005-03-15 EC EC2005005676A patent/ECSP055676A/es unknown
- 2005-03-16 HR HR20050248A patent/HRP20050248A2/hr not_active Application Discontinuation
- 2005-03-17 MA MA28152A patent/MA27438A1/fr unknown
- 2005-03-18 CO CO05025665A patent/CO5550472A2/es not_active Application Discontinuation
- 2005-04-15 NO NO20051826A patent/NO20051826L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EA200500342A1 (ru) | 2005-08-25 |
MA27438A1 (fr) | 2005-07-01 |
TW200409771A (en) | 2004-06-16 |
IS7710A (is) | 2005-02-24 |
MXPA05002007A (es) | 2005-04-28 |
UY27976A1 (es) | 2004-04-30 |
PE20050132A1 (es) | 2005-03-21 |
BR0314393A (pt) | 2005-07-19 |
NO20051826L (no) | 2005-04-15 |
AP2005003250A0 (en) | 2005-03-31 |
PA8582601A1 (es) | 2004-05-26 |
KR20050057404A (ko) | 2005-06-16 |
WO2004026864A1 (fr) | 2004-04-01 |
JP2006503106A (ja) | 2006-01-26 |
PL375981A1 (en) | 2005-12-12 |
OA12923A (en) | 2006-10-13 |
EP1546143A1 (fr) | 2005-06-29 |
ECSP055676A (es) | 2005-07-06 |
CA2499326A1 (fr) | 2004-04-01 |
AR041260A1 (es) | 2005-05-11 |
CO5550472A2 (es) | 2005-08-31 |
RS20050195A (en) | 2007-08-03 |
AU2003263413A1 (en) | 2004-04-08 |
US20040138230A1 (en) | 2004-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20050248A2 (en) | Heterocyclic substituted piperazines for the treatment of schizophrenia | |
ES2358631T7 (es) | Benzotiofenos con piperazin sustituido para el tratamiento de enfermedades mentales | |
AU2005315914A1 (en) | Bi- and tricyclic substituted phenyl methanones as glycine transporter I (GlyT-1) inhibitors for the treatment of Alzheimer's disease | |
JP2010536789A (ja) | 5−ht6受容体親和性を有する3’置換化合物 | |
US20060173179A1 (en) | Azabenzoxazoles for the treatment of CNS disorders | |
WO2010002802A1 (fr) | Composés aza-indole substitué par un résidu pyrrolidine ayant une affinité pour le récepteur 5-ht<sb>6</sb> | |
MXPA06007654A (es) | Derivados de piperidina n-sustituidos. | |
BRPI0807602A2 (pt) | Compostos 6' substituídos com afinidade pelo receptor 5-ht6. | |
WO2006051410A1 (fr) | Azabenzoxazoles pour le traitement de troubles du systeme nerveux central | |
KR100588249B1 (ko) | 테트라하이드로벤즈인돌 유도체 | |
DK2616460T3 (en) | HETEROCYCLIC COMPOUNDS FOR TREATMENT OR PREVENTION OF DISEASES CAUSED BY decreased neurotransmission of serotonin, norepinephrine or dopamine | |
KR20070112228A (ko) | 정신분열증을 치료하기 위한테트라하이드로-피리도아제핀-8-온 및 관련 화합물 | |
PL191863B1 (pl) | Tetrahydro-૪-karboliny | |
US20100029629A1 (en) | Acyclic compounds having 5-ht6 receptor affinity | |
US20040067960A1 (en) | Heterocyclic substituted piperazines for the treatment of schizophrenia | |
JP6033085B2 (ja) | 三環式誘導体ならびにそれらの医薬用途および組成物 | |
US20060166974A1 (en) | Azabenzoxazoles for the treatment of CNS disorders | |
MXPA05003658A (es) | Derivados de piperazina sustituidos con oxindol. | |
WO2006051413A1 (fr) | Azabenoxazoles dans le traitement des troubles du snc |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
A1OB | Publication of a patent application | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20060810 Year of fee payment: 4 |
|
OBST | Application withdrawn |